Pür Insights
A Realistic Starting Point for Women Over 40
A Realistic Starting Point for Women Over 40 Over the past month we've written a dozen posts about women's health after 40: creatine, protein, muscle, bone, brain fog, hydration, skin, and the "hormone balancing" aisle. Each one dug into a single question and followed the research wherever it went, including the places where it went against what supplement companies, us included, might prefer to say. This post pulls it together into something more useful than a reading list: an order of operations. If you're in your 40s and want to do something sensible for how the next few decades go, where do you actually start? The honest answer is shorter than most people expect. A few things have strong evidence and matter a great deal. One supplement has a reasonable case. Quite a lot of what's marketed to women in this decade can be safely skipped. And some questions aren't supplement questions at all. What's actually changing in this decade It helps to know what you're responding to. Muscle and strength. The European Working Group on Sarcopenia in Older People, in its 2019 consensus published in Age and Ageing, describes muscle mass and strength peaking up to around age 40, holding through midlife, then declining. Beyond age 50, it cites losses of 1 to 2 percent per year in leg muscle mass and 1.5 to 5 percent per year in strength. Strength falls faster than size, which is why that group made strength, not mass, its primary diagnostic criterion. Hormones. Menopause arrives at an average age of 51, with perimenopause typically beginning in the mid-to-late 40s, though timing varies widely. For women, the documented acceleration in muscle loss and the reduced response to training and protein appear mainly around and after menopause. Research specifically reports no significant sex difference in how middle-aged adults respond to training and nutrition. So the 40s are less a cliff than the beginning of a slope. Bone, skin, sleep, and thinking. Bone loss and skin collagen loss both speed up as estrogen falls. Sleep often gets more disrupted. And many women notice changes in memory and focus, which the SWAN study, one of the largest long-term studies of midlife women, found to be real but modest and, so far, apparently temporary. What changes less than you've been told. Two things came up repeatedly in our research. Hormonal shifts change some of the body's set points for fluid balance, but a 2022 review of the menstrual cycle research found no consistent effect on fluid retention, sweat rates, or electrolyte losses. And "hormone balance" isn't a measurable state at all, because healthy hormones are supposed to fluctuate. With that in mind, here's the order we'd suggest. Step 1: Start strength training, and keep it simple If you do one thing from this post, make it this. Across every topic we looked at this month, resistance training kept showing up as the intervention with the strongest evidence. The World Health Organization's 2020 guidelines, published by Bull and colleagues in the British Journal of Sports Medicine, recommend muscle-strengthening activity at moderate or greater intensity, involving all major muscle groups, on two or more days a week. For older adults, they add varied activity emphasizing balance and strength training on three or more days a week to help prevent falls. The WHO describes moderate intensity, relative to your own capacity, as usually a 5 or more out of 10. Two details make this more achievable than it sounds. First, the WHO review found no evidence that higher volumes of muscle-strengthening activity add further health benefit, so you don't need to live in a gym. Second, in research on older adults, training does most of the work. A network meta-analysis of 38 randomized trials found that adding protein supplements to a resistance training program produced no difference on any outcome compared with the training program alone. In practice, that means two or three sessions a week covering legs, hips, back, chest, core, shoulders, and arms, with the effort or weight increasing gradually over time. If you're new to this, a qualified coach for the first few sessions is a good investment. And track strength, not just the scale. Because strength declines faster than muscle size, measures like grip strength and how easily you can rise from a chair without using your arms tell you more about what matters than body weight does. For the detail, see our posts on muscle loss in midlife and on strength training after 40. Step 2: Get enough protein, spread across your meals Protein is the one nutritional input with a direct, well-established role in maintaining muscle, so it comes next. The official recommended dietary allowance is 0.8 grams per kilogram of body weight per day. Several lines of research suggest that's a floor rather than an ideal. Studies using a method called indicator amino acid oxidation estimated requirements closer to 1.2 grams per kilogram, without finding differences by sex or age. Expert groups go further for older adults: the PROT-AGE Study Group recommends 1.0 to 1.2 grams per kilogram, and the ESPEN Expert Group 1.0 to 1.5 grams per kilogram. It's worth being precise that those two recommendations were written for people over 65. In your 40s, the case is about building good habits before the harder years arrive, not a sudden jump in what you need. How you spread it matters too. PROT-AGE describes a per-meal threshold for older adults of roughly 25 to 30 grams of protein containing about 2.5 to 2.8 grams of leucine. A lot of people get most of their protein at dinner and very little at breakfast. Moving some of it earlier is one of the easiest changes available, and it doesn't require eating more overall. One honest note on protein powders, including ours. If you're using a powder to hit that per-meal threshold, a whey-dominant protein does it more efficiently than a collagen-dominant one, because whey is much richer in leucine. Our blend leans toward collagen, so it isn't the most efficient tool for that particular job. For the full picture, see our post on protein after 40. Step 3: Treat sleep as part of the plan Sleep didn't get its own post this month, but it kept surfacing in almost every topic. In SWAN, the study behind our brain fog post, the researchers point to sleep and mood as factors that worsen during the menopause transition and that affect memory and focus. Their guidance links lack of sleep directly to poor memory and difficulty concentrating. In our magnesium research, sleep was the one area where the case for magnesium held up reasonably well, and it wasn't actually a hormonal effect, but a general one in a group of people who often sleep badly. If night sweats are waking you, the mechanism suggests a practical step. Robert Freedman's research found that in women with hot flashes, the body's temperature buffer between sweating and shivering narrows to almost nothing, so small rises in core temperature trigger a flush. Keeping your bedroom cool targets that directly, and his review notes that cooling the body reduces hot flashes. If your sleep is badly disrupted, that's worth raising with a clinician. Better sleep may do more for your energy and focus than anything on this list. For more, see our posts on brain fog in midlife, magnesium and hormonal change, and hydration and hormonal shifts. Step 4: Wear a tested sunscreen every day For skin, the strongest evidence we found had nothing to do with nutrition. The Nambour trial, published by Hughes and colleagues in the Annals of Internal Medicine in 2013, randomly assigned 903 adults under 55 to daily or occasional use of a broad-spectrum sunscreen and followed them for four and a half years. The daily group showed no detectable increase in skin aging, and 24 percent less skin aging than the occasional-use group. The same trial tested a beta-carotene supplement and found no overall effect. Use a broad-spectrum sunscreen with an SPF rating and a Drug Facts label. Our Sun Balm is not one, and we've said so before. A moisturizer, including our tallow products, helps with dryness and the feel of the skin's surface, but it doesn't protect against UV or rebuild collagen. For the detail, see our post on skin changes in your 40s. Step 5: If you want one supplement, creatine has the clearest case Once the first four steps are in place, creatine monohydrate is the supplement with the most consistent evidence for women in this decade, as long as you're training. The evidence is led by strength. A 2021 review by Smith-Ryan and colleagues in Nutrients concluded that creatine appears effective for strength and exercise performance in pre-menopausal women, and found that post-menopausal women may benefit in muscle size and function at higher doses. A three-level meta-analysis in older adults found a significant strength benefit when creatine was added to resistance training, with an effect size of 0.31 and a 95 percent confidence interval of 0.18 to 0.45, though no significant effect on muscle mass. That's a modest, real benefit, not a transformation. The standard dose is 3 to 5 grams a day of creatine monohydrate. Loading isn't necessary. Without it, your muscles reach full saturation in about three to four weeks. Timing doesn't matter much; consistency does. The common fears mostly don't hold up. A 2023 randomized trial found no significant increase in body weight in women across any phase of the menstrual cycle. A 2025 randomized trial found no effect on hair or on the hormone DHT, though it was in young men. And reviews spanning more than a decade have found no increase in dehydration or cramping. The real caveats: there are no human trials of creatine supplementation during pregnancy, data on perimenopausal women specifically is still limited, and anyone with kidney disease should talk to a doctor first. If you have blood tests, tell your doctor you take creatine, because it raises a kidney marker called creatinine without indicating kidney damage. We sell creatine monohydrate. For all the detail, see our posts on creatine for women, creatine dosing, and creatine myths. What you can probably skip This is the list that saves money, and it's built on the same research. Vitamin D for fracture prevention, if you're not deficient. The VITAL trial, published by LeBoff and colleagues in the New England Journal of Medicine in 2022, gave 25,871 adults vitamin D3 or a placebo and found no reduction in fractures, even in people with lower vitamin D levels at the start. In 2024, the US Preventive Services Task Force issued a draft recommendation against vitamin D supplementation for preventing fractures and falls in adults living in the community, and the Endocrine Society advised against routine supplementation in healthy adults under 75. Correcting a genuine deficiency is still worthwhile, and some groups, such as adults over 75, are still advised to supplement. We sell a vitamin D3 and K2 product, and this evidence complicates the case for it. Collagen supplements for skin aging. A 2025 meta-analysis of 23 trials by Myung and Park in the American Journal of Medicine found benefits when all trials were pooled, but no effect in the high-quality trials or in trials not funded by industry. Industry disputes that interpretation. Our protein blend is mostly collagen, and we wouldn't recommend buying it as a wrinkle treatment. "Hormone balancing" blends and "adrenal support." A 2016 systematic review of 58 studies by Cadegiani and Kater concluded there is no substantiation that "adrenal fatigue" is a real medical condition. Cochrane reviews found no conclusive benefit from phytoestrogens for hot flushes, apart from a narrow signal for high-dose genistein, and evidence on black cohosh that is best described as conflicting. Brain fog supplements. The largest trial of ginkgo, involving more than 3,000 older adults, found no effect on dementia or cognitive decline. The European Food Safety Authority concluded in 2024 that a link between creatine and better cognition hasn't been established. Standalone BCAAs, if your protein is adequate. A 2017 review by Robert Wolfe concluded that the claim that BCAAs alone stimulate muscle building is unwarranted, because muscle needs all the essential amino acids, which complete protein already provides. High-dose vitamin C and E around your workouts. In a 2016 randomized trial by Bjørnsen and colleagues, older men taking them alongside strength training gained less muscle than those on placebo. Other studies found smaller or no effects, but there's no good evidence they help training. Electrolytes "for your hormones." Electrolytes are genuinely useful for heavy sweating, long efforts in the heat, and very low-carb diets. The research doesn't support taking them because of hormonal changes alone. We sell an electrolyte product, and those first reasons are the honest ones. When it isn't a supplement question Some situations need a doctor rather than a product, and recognizing them is part of a realistic plan. See a doctor if memory changes come on suddenly. SWAN's guidance specifically flags this. Gradual, on-and-off word-finding trouble in your late 40s fits the research pattern. Sudden change doesn't. Get persistent fatigue, weight changes, mood changes, or changes in your cycle checked. These overlap with conditions, such as thyroid disorders, that standard blood tests can identify. If you've been diagnosed with osteoporosis or osteopenia, kidney disease, or another condition, work with your clinician rather than substituting nutrition for treatment. If you're pregnant or trying to become pregnant, check supplements with your obstetric provider first. And questions about hormone therapy belong in a conversation with a clinician, who can weigh the options against your own health history. What "realistic" means The word is in the title for a reason. None of the steps above will make you feel like a different person in a fortnight. Strength builds over months of consistent training. Creatine takes about three to four weeks to saturate your muscles at a standard dose, and its effect is modest. Sleep and sun protection pay off over years rather than days. What these steps have in common is that each is backed by evidence you can look up, and together they address the changes that actually define this decade: strength, muscle, bone, skin, sleep, and focus. That's a smaller, less exciting list than the supplement aisle offers. It's also one that holds up. The honest summary For women over 40, the realistic starting point is short. Strength train two or more days a week, covering all the major muscle groups, as the WHO recommends, and track your strength. Eat enough protein and spread it across your meals, including breakfast. Protect your sleep, and keep your bedroom cool if hot flashes are disrupting it. Wear a tested broad-spectrum sunscreen every day. If you want one supplement on top of that, creatine monohydrate at 3 to 5 grams a day has the clearest case, as long as you're training. Beyond that, a lot can be skipped: vitamin D for fracture prevention if you're not deficient, collagen for wrinkles, hormone-balancing blends, adrenal support, brain fog supplements, standalone BCAAs, and high-dose antioxidants around your workouts. Some of those are products we sell, and we've said so in each post. And some things aren't supplement questions at all. Sudden memory changes, persistent unexplained symptoms, diagnosed conditions, pregnancy, and hormone therapy all belong with a clinician. That's the whole plan. It fits on one page, and every part of it comes with a study you can check.
Learn more
Why Most "Hormone Balancing" Supplements Are Marketing
Why Most "Hormone Balancing" Supplements Are Marketing Walk through any supplement aisle or scroll for a few minutes and you'll find the same promise in a dozen forms. Hormone balance. Hormonal harmony. Support for "your cycle," "your adrenals," "your changing body." The packaging is usually calm and botanical. The claims are usually vague. That vagueness isn't an accident, and it's the most useful thing to understand about this category. "Hormone balance" sounds like a specific medical outcome, but it isn't one. It can't be measured, which means it can't be tested, which means a product promising it can never really be shown to fail. This post looks at why the phrase works so well as marketing, what happens when the most popular ingredients are tested against specific symptoms, and how to read these labels with a clearer eye. We're not naming any brands. The issue is the category and the language it runs on, not any one company. "Balance" describes something hormones don't do The first problem is conceptual. The idea of hormonal "balance" suggests a steady, correct level your body should sit at, which supplements can nudge you back toward. Healthy hormones don't work that way. They're supposed to move. Estrogen and progesterone rise and fall across the menstrual cycle in a predictable pattern. Cortisol follows a daily rhythm, peaking shortly after waking and falling through the day. Across the menopause transition, hormone levels fluctuate and then shift to a new pattern. We've covered several of these in earlier posts, including how estrogen changes the body's thirst threshold across the cycle and how SWAN, one of the largest studies of midlife women, tracked cognition through the transition. None of that is imbalance. It's normal physiology. So when a product promises to "balance" hormones, the obvious question is: balance them to what? There's no single target, and the product never says. That's what makes the phrase so commercially useful. It describes a vague sense of things being off, which almost everyone feels at some point, and offers to fix it without ever committing to a result anyone could check. Why the claims stay vague: the legal framework There's also a structural reason the language in this category is so soft, and it comes from how supplements are regulated in the United States. Under the Dietary Supplement Health and Education Act of 1994, supplements are regulated as a category of food rather than as drugs. They don't need FDA approval before going on sale, and the FDA doesn't evaluate whether they work. Manufacturers can make what are called structure/function claims, statements about how a product affects the body's normal structure or function, as long as they don't claim to diagnose, treat, cure, or prevent a disease. Products making these claims carry a standard disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." That line is worth reading slowly the next time you see it. It's the manufacturer telling you, in a legally required sentence, that no regulator has checked the claim above it. Phrases like "supports hormonal balance" sit comfortably inside this framework. They describe a function in general terms, avoid naming a disease, and don't need to be backed by the kind of trial a drug would need. That isn't illegal. It's how the system is designed. But it means the confidence of the wording tells you nothing about the strength of the evidence. The clearest example: "adrenal fatigue" If you want to see how a vague hormonal concept can support an entire product category without strong evidence behind it, "adrenal fatigue" is the clearest case. The idea is that chronic stress wears out the adrenal glands, leaving them unable to produce enough cortisol, which supposedly causes tiredness, brain fog, and low mood. A whole range of "adrenal support" supplements is sold on that premise. In 2016, Flavio Cadegiani and Claudio Kater of the Federal University of São Paulo set out to check whether the condition had any scientific basis. Their systematic review, published in BMC Endocrine Disorders, volume 16, article 48, searched PubMed, MEDLINE, and the Cochrane databases through April 2016. From 3,470 articles, 58 studies met their criteria, 33 in healthy people and 25 in people with symptoms. The tests used most often were awakening cortisol, the cortisol awakening response, and salivary cortisol rhythm. They found what they described as an almost systematic pattern of conflicting results across these studies, regardless of how well the tests were validated. Their conclusion was blunt: there is no substantiation that "adrenal fatigue" is an actual medical condition, and adrenal fatigue is still a myth. They also noted that no endocrinology society recognizes it, and that their findings corroborated an existing warning from the Endocrine Society. It's fair to add that some practitioners have pushed back, arguing that stress-related changes in cortisol patterns are worth studying in their own right. That's a reasonable research question. It's also a different claim from the one adrenal support supplements are typically sold on, which is that a recognizable condition exists and a product can fix it. Tiredness, poor concentration, and low mood are real and worth taking seriously. They just have many possible causes, several of which a doctor can actually test for. What happens when ingredients are tested against something specific The vague "balance" claim can't be tested. But many of the ingredients in these products can be, against specific symptoms. The most studied are those aimed at menopausal symptoms, particularly hot flushes, because that's a measurable outcome. Looking at how they perform is revealing. Black cohosh. Black cohosh is one of the most widely used herbs for menopausal symptoms. A Cochrane systematic review by Leach and Moore, published in 2012, pooled 16 randomized trials involving 2,027 women, who took an average of 40 milligrams a day for an average of 23 weeks. For hot flush frequency, there was no significant difference between black cohosh and placebo. The pooled difference was 0.07 flushes per day, with a 95 percent confidence interval of negative 0.43 to 0.56 and a p-value of 0.79, based on three trials with 393 women. There was also no significant difference in menopausal symptom scores. Evidence on safety was inconclusive because of poor reporting. The reviewers concluded there was insufficient evidence to support the use of black cohosh for menopausal symptoms, while noting that the uncertain quality of most studies meant further research was warranted. The NIH Office of Dietary Supplements summarizes the review as finding insufficient evidence to either support or oppose its use. It would be unfair to stop there, because other analyses disagree. The Merck Manual describes the evidence on black cohosh as conflicting. It notes a network meta-analysis that found black cohosh reduced vasomotor symptoms compared with placebo, though less effectively than hormonal treatments, and a later meta-analysis of 22 randomized trials with 2,310 women reporting improvements in overall menopausal symptoms, hot flushes, and physical symptoms, but not in depressive or anxiety symptoms. So black cohosh isn't a clean failure. It's an ingredient that has been studied a great deal and still sits at "conflicting," depending on which extract and which analysis you look at. That's a long way from the confidence on the label. Phytoestrogens. Plant compounds with weak estrogen-like activity, found in soy and red clover among other sources, are the other big category. A Cochrane review by Lethaby and colleagues, published in 2013, included 43 randomized trials with 4,084 participants, covering dietary soy, soy extracts, red clover extracts, genistein extracts, and other phytoestrogens. The headline finding was that there was no conclusive evidence that phytoestrogen supplements reduce the frequency or severity of hot flushes and night sweats, with many trials small, short, and of questionable quality. Overall, there was no indication that most types of phytoestrogen worked better than no treatment. There was one specific exception. Four trials, not combined in a meta-analysis, suggested that extracts with high levels of genistein, above 30 milligrams a day, consistently reduced the frequency of hot flushes. The reviewers flagged this as needing further investigation. On safety, they found no evidence of estrogen-like stimulation of the womb lining or vagina, or other adverse effects, with use of up to two years. Notice how specific that one positive signal is: a particular compound, at a particular dose, for a particular symptom. That's the kind of claim that can be checked. "Supports hormonal balance" is not. Magnesium. We covered magnesium and hormonal change in detail in an earlier post. Briefly: a 2025 systematic review in Nutrition Reviews named magnesium among the interventions with insufficient evidence for psychological premenstrual symptoms, and the widely cited positive result for hot flashes came from a small pilot study that shrank in a larger placebo-controlled trial. The pattern across all three is consistent. When the best-known "hormone" ingredients are tested against specific, measurable symptoms, the results range from no effect to conflicting to a narrow signal at a specific dose. That's the honest ceiling of the evidence for the most-studied ingredients in the category. Many of the less-studied ingredients that appear in these blends have their own evidence bases, some better than others, and the right way to judge any of them is the same: against a specific symptom, at the dose that was actually tested. The hidden cost of a vague promise A supplement that doesn't work is a waste of money. A supplement with a vague hormonal promise can carry a less obvious cost. The symptoms these products target, such as tiredness, weight changes, mood shifts, irregular periods, and trouble sleeping, overlap with conditions that a doctor can actually diagnose, often with a straightforward blood test. Thyroid disorders are a common example. If a product reframes those symptoms as a vague "imbalance" that a capsule can address, it can make it easier to put off the appointment that would find the real cause. There's also a practical problem on the label itself. Many hormone-focused products are proprietary blends that list ingredients without disclosing how much of each is included. That makes it impossible to compare the product to the research. The one clear positive signal in the phytoestrogen review applied to genistein above 30 milligrams a day. If a label lists "soy isoflavone blend" without saying how much genistein is in it, you have no way of knowing whether you're anywhere near that threshold. How to read a "hormone" supplement label A few questions cut through most of the marketing in this category. What specific symptom is this for? "Balance," "harmony," and "support" aren't outcomes. If the product can't name what it's meant to change, there's nothing to evaluate. Which ingredient is supposed to do that, and at what dose? Look for single ingredients with disclosed amounts that you can match against published research. Proprietary blends with undisclosed amounts make this impossible. Does the claim rest on a recognized condition? Be wary of products built around concepts like "adrenal fatigue" that the relevant medical specialty doesn't recognize. Does it imply it can replace a diagnosis? If you have symptoms that are persistent or affecting your life, a product that offers to fix them without anyone working out the cause is skipping the most important step. Our own catalog isn't exempt It would be easy to write this post as if it only applied to other companies. It doesn't. We sell shilajit, and the main human evidence on its hormonal effects is a single small randomized trial in men aged 45 to 55, which is how we've described it when we've written about it. We sell a magnesium complex, and our own post on magnesium and hormonal change concluded that the evidence for hormone-specific benefits is weak, with sleep being the more defensible reason to take it. We don't sell anything marketed as a hormone-balancing product, and given everything above, we don't plan to. The standard we'd suggest applying to any brand, including us, is simple: a specific claim, about a specific ingredient, at a specific dose, backed by a specific study you can look up. What's actually worth doing If you're dealing with symptoms you think might be hormonal, a few steps are more useful than any product. See a doctor if symptoms are persistent, new, or affecting your daily life. Many of the conditions behind tiredness, weight changes, mood shifts, or cycle changes can be identified with standard tests, and identifying them is what makes effective treatment possible. For menopausal symptoms in particular, there are evidence-based options with far stronger research behind them than the supplements above. What's appropriate for you depends on your health history, so it's a conversation for a clinician rather than something to decide from a label or a blog post. And don't underestimate the basics. Sleep, stress, and physical activity affect how you feel through every hormonal stage, and they're the foundation that anything else builds on. The honest summary "Hormone balancing" is marketing language because it describes something hormones don't do. Healthy hormones are meant to fluctuate across the cycle, the day, and the decades, so a promise to "balance" them never has to say what the target is. US supplement law allows broad structure/function claims without FDA review, as long as products carry a disclaimer saying no regulator has evaluated them, and vague hormonal wording fits that framework easily. When the concept is tested directly, it often doesn't hold. A 2016 systematic review of 58 studies concluded that "adrenal fatigue" has no substantiation as a medical condition. When the most popular ingredients are tested against specific symptoms, the results are underwhelming: a 2012 Cochrane review found no significant difference between black cohosh and placebo for hot flushes, though other analyses are more positive and the overall evidence is best described as conflicting. A 2013 Cochrane review of 43 trials found no conclusive evidence that phytoestrogens reduce hot flushes, with one narrow exception for high-dose genistein above 30 milligrams a day. None of that means every ingredient in these products is useless. It means the useful questions are specific ones: which symptom, which ingredient, what dose, and what study. A label that can't answer them is selling a feeling, not a result.
Learn more
Skin Changes in Your 40s: What Nutrition Can and Can't Address
Skin Changes in Your 40s: What Nutrition Can and Can't Address Somewhere in your 40s, skin often starts behaving differently. It gets drier. It feels thinner. Lines that used to fade by lunchtime stay put. And right on cue, the marketing arrives: collagen powders, "beauty from within" capsules, antioxidant blends promising to turn back the clock from the inside. Some of that has a basis in real biology. A lot of it doesn't, and the research on this is unusually clear in places. The honest picture is that the biggest drivers of skin aging in this decade are hormonal change and sun exposure, and nutrition has limited reach over either. What diet can influence is real but narrower than the products suggest. This post separates the two, with the studies behind each claim. What's actually changing Two broad processes drive skin aging. Intrinsic aging is the internal, largely programmed part, which in women is heavily shaped by hormones. Extrinsic aging comes from outside, and the dominant factor there is ultraviolet light. The hormonal part. Estrogen supports the cells in the skin that make collagen, so when estrogen falls, collagen production falls with it. The most frequently cited data here comes from work by Brincat and colleagues in the 1980s. A 2007 review by Stevenson and Thornton in Clinical Interventions in Aging summarizes it: in postmenopausal women, skin thickness decreases by about 1.13 percent per postmenopausal year, with collagen content falling about 2 percent per postmenopausal year. The review also notes that collagen types I and III are thought to decrease by as much as 30 percent in the first five years after menopause. Two details in that summary matter. First, the decline in skin thickness and collagen appeared to track the length of estrogen deficiency more closely than chronological age. Two women of the same age can be in very different places depending on where they are in the menopause transition. Second, notice the phrasing: "thought to decrease by as much as." The 30 percent figure is now everywhere, sometimes under the name "collagen cliff," but it comes from small biopsy studies from several decades ago and is an upper estimate rather than a typical outcome. It's real research. It's also older and less precise than its popularity suggests. For most women, the 40s are the perimenopausal years, and menopause itself comes around age 51 on average. So the steepest part of this hormonal decline usually arrives a bit later. The 40s are when it starts. The sun part. This is where the strongest intervention evidence in the whole field sits, and it isn't a nutrient. The Nambour trial, published by Hughes, Williams, Baker, and Green in the Annals of Internal Medicine in 2013, volume 158, pages 781 to 790, randomized 903 adults younger than 55 in Nambour, Australia. Participants were assigned to daily or discretionary use of a broad-spectrum sunscreen, and separately to 30 milligrams of beta-carotene or a placebo. Assessors who didn't know who was in which group graded changes in skin microtopography over four and a half years. The daily sunscreen group showed no detectable increase in skin aging over that period. Skin aging was 24 percent less in the daily sunscreen group than in the discretionary group, with a relative odds of 0.76 and a 95 percent confidence interval of 0.59 to 0.98. The authors concluded that regular sunscreen use retards skin aging in healthy, middle-aged men and women. Hold onto the beta-carotene arm. We'll come back to it. What nutrition can't address This is the part most "beauty from within" marketing skips, so it's worth being direct about it. It can't replace estrogen. The collagen loss described above is driven by falling estrogen signalling to the cells that build collagen. No food or supplement replicates that signal. Eating well supports the raw materials your skin uses, but it doesn't restore the hormonal instruction to use them at the same rate. Hormone therapy is a separate medical decision with its own evidence and risks, and it belongs in a conversation with a clinician rather than a supplement brand's blog, so we're leaving it there. It can't undo sun damage, and the best trial on this says so. Back to Nambour. The same randomized trial that showed sunscreen working also tested a nutritional antioxidant against placebo. Beta-carotene supplementation had no overall effect on skin aging. The authors noted contrasting associations in subgroups with different levels of aging at the start, and said further study would be needed to definitively rule out either benefit or harm. But in a well-designed trial lasting four and a half years, the topical intervention worked and the nutritional one didn't. That's about as clean a comparison as this field offers. Collagen supplements: the evidence is weaker than it looks. Collagen powders are the most heavily marketed nutrition product for aging skin, and for a while the research seemed encouraging. Several meta-analyses pooled randomized trials and found improvements in skin hydration and elasticity. A 2023 meta-analysis of 26 randomized controlled trials, for example, concluded that hydrolyzed collagen can have positive effects on skin health, while calling for larger trials. Then a 2025 meta-analysis asked a question the earlier ones hadn't. Myung and Park, publishing in the American Journal of Medicine, volume 138, pages 1264 to 1277, analyzed 23 randomized trials with 1,474 participants, and the study itself received no funding. Pooling all 23, collagen supplements significantly improved skin hydration, elasticity, and wrinkles. But when the authors split the trials by funding source, the studies that did not receive funding from pharmaceutical or supplement companies showed no effect on hydration, elasticity, or wrinkles, while the funded studies did show significant effects. Splitting by methodological quality gave a similar picture: high-quality studies showed no significant effect in any category, while low-quality studies showed a significant improvement in elasticity. That's a striking result, and it's fair to report the response to it as well. Industry representatives pushed back, arguing that industry-funded studies aren't necessarily lower quality, and pointing out that most of the industry-funded trials in the analysis scored reasonably well on a standard quality scale. A 2026 narrative review in Applied Sciences took a middle position: it described collagen at 2.5 to 10 grams a day for at least 8 to 12 weeks as associated with improved hydration, elasticity, and wrinkle depth, while stating that results are inconsistent and that the effect is markedly weaker or not statistically significant in the highest-quality studies and those independent of industry support. The fair summary: the case for collagen supplements improving aging skin is real enough to have been studied seriously, and fragile enough that it largely disappears when you look only at the strongest and most independent trials. We should be upfront about why this matters to us. Our protein blend is majority hydrolyzed collagen. Given this evidence, we're not going to tell you it will reverse skin aging. If you take it, take it as a protein source, not as a wrinkle treatment. What nutrition can plausibly influence None of this means diet is irrelevant to skin. It means the realistic claims are more modest and more general than a single product can offer. Overall dietary pattern shows up in the data. The most relevant study for this age group comes from Cosgrove and colleagues, published in the American Journal of Clinical Nutrition in 2007, volume 86, pages 1225 to 1231. Using data from the first National Health and Nutrition Examination Survey, they examined 4,025 women aged 40 to 74. Nutrient intake was estimated from 24-hour recall, and dermatologists examined each woman's skin for wrinkled appearance, age-related dryness, and skin thinning. Higher intakes of vitamin C and linoleic acid, and lower intakes of fat and carbohydrate, were associated with better skin-aging appearance, independent of other factors known to affect skin aging. A 50-gram increase in carbohydrate intake was associated with higher odds of a wrinkled appearance, with an odds ratio of 1.36. Higher fat intake was also associated with greater likelihood of a wrinkled appearance. Higher linoleic acid intake was associated with a lower likelihood of age-related dryness, with an odds ratio of 0.75, and with a lower likelihood of skin thinning. The caveats are important. This was a cross-sectional study, meaning it measured diet and skin at one point in time. It shows association, not cause. A single 24-hour diet recall is a rough snapshot of what someone usually eats. And women who eat more fruit and vegetables may differ in many other ways, such as sun habits, that the analysis may not fully capture. It's useful evidence that diet and skin appearance travel together. It isn't proof that changing one item on your plate will change your skin. Vitamin C is a genuine requirement. Vitamin C is a required cofactor for the enzymes that build and stabilize collagen. That's basic biochemistry, not marketing, and it's why severe deficiency affects skin and connective tissue. What it supports is getting enough. It doesn't mean that taking more than you need makes your skin build extra collagen, and there isn't good evidence that it does. For most people, a diet with regular fruit and vegetables covers it. Protein matters as a building block. Collagen is a protein, so skin needs adequate dietary protein to maintain it. In the Cosgrove data, women with a wrinkled appearance had lower protein intakes than women without one, though that's an unadjusted comparison and shouldn't be over-read. We've written about protein needs after 40 separately. The relevant point here is that getting enough protein overall supports skin as part of supporting the whole body. Linoleic acid is an essential fat with a skin role. Linoleic acid is an essential omega-6 fatty acid that the body uses in the lipids that make up the skin's barrier. Its association with less dryness in the Cosgrove study fits that role. It's found in many nuts, seeds, and plant oils. Again, the point is adequacy as part of a varied diet, not megadosing. Put simply, nutrition looks most useful for making sure your skin isn't short of what it needs. That's genuinely worth doing. It's also a different promise from reversing the changes driven by hormones and sun. Where topical care fits, including ours The changes people notice most in their 40s aren't all in the deeper layers of the skin. Dryness and a rougher surface happen at the outer barrier, and that's a place where what you put on your skin can make a measurable difference. We covered this in detail in our post on tallow balm and hydration. Moisturizers work by reducing water loss through the skin's surface, through occlusive and emollient effects. Tallow-based products sit in the emollient category, integrating into the outer layer's lipids and helping with dryness and texture. The honest limit is the same one that applies to collagen powders, from the other direction. A moisturizer, including ours, works on the surface. It can make dry skin feel and look better and support the outer barrier. It doesn't rebuild collagen in the deeper layers or reverse wrinkles caused by collagen loss. We'd rather you buy a balm for what it does than expect it to do something it can't. And for sun protection, use a tested, broad-spectrum sunscreen with an SPF rating and a Drug Facts label. Our Sun Balm is not one, and we've said so directly before. The Nambour results came from daily use of a proper broad-spectrum sunscreen, and that's the product category the evidence supports. What's actually worth doing Based on the research above, the priorities line up in a fairly clear order. Use a broad-spectrum sunscreen every day on exposed skin. It's the intervention with the strongest randomized evidence for slowing visible skin aging, and in the Nambour trial it outperformed the nutritional antioxidant tested alongside it. Eat a varied diet with enough vitamin C, protein, and essential fats. The evidence supports this as a way of not shortchanging your skin, consistent with what Cosgrove and colleagues found in women aged 40 to 74. Moisturize for dryness. It works at the surface, where a lot of what people notice in their 40s actually happens. Be skeptical of products promising to reverse skin aging from the inside. The best-known category, collagen supplements, shows effects that mostly vanish in the highest-quality and most independent trials. If you want to address changes that go deeper, a dermatologist can walk you through evidence-based topical treatments. Hormone-related questions belong with your doctor. The honest summary The skin changes many women notice in their 40s are driven largely by two things nutrition can't reverse. Falling estrogen reduces collagen production, with older biopsy studies estimating losses of about 2 percent per postmenopausal year and as much as 30 percent in the first five years after menopause. And sun exposure drives visible aging, which daily broad-spectrum sunscreen reduced by 24 percent in a randomized trial of 903 adults. That same trial found no overall effect from a beta-carotene supplement. A 2025 meta-analysis of 23 trials found that collagen supplements' apparent benefits for skin largely disappeared in high-quality studies and in studies not funded by industry, though the industry disputes that interpretation. What nutrition can do is narrower and still worthwhile: provide the vitamin C, protein, and essential fats skin needs, as part of an overall dietary pattern that, in a large study of middle-aged women, was associated with better skin-aging appearance. That's a smaller promise than most skin supplements make. It's also one the evidence actually supports.
Learn more
Creatine Myths That Keep Women From Trying It
Creatine Myths That Keep Women From Trying It Creatine is one of the most researched supplements in existence, and for most of its history it was marketed almost entirely to men. The tubs were black, the labels were loud, and the promise was size. So it's not surprising that when women ask about it, the questions tend to start from worry rather than curiosity. Will it make me bulky? Will I bloat? Is it basically a steroid? Will my hair fall out? Those are fair questions, and they deserve better answers than "trust me, it's fine." In 2021, eleven researchers, including Abbie Smith-Ryan, one of the leading investigators on creatine in women, published a review in the Journal of the International Society of Sports Nutrition specifically to address the most common questions and misconceptions about creatine. Antonio and colleagues, volume 18, article 13, worked through twelve of them, from water retention to whether creatine only works for men. A Part II followed at the end of 2024. This post takes the myths women raise most often and checks each one against the research, including the places where the evidence is thinner than it should be, or was gathered mostly in men. One note before starting. Many of the researchers who study creatine most closely have disclosed relationships with supplement companies, and that's worth keeping in mind. Where it's relevant below, we'll point it out. Where independent research reaches the same conclusion, we'll point that out too. Myth 1: "Creatine will make me bulky" This is the most common worry, and it rests on a misunderstanding of what creatine actually does. Creatine doesn't build muscle on its own. It increases the amount of phosphocreatine stored in your muscles, which helps regenerate energy quickly during short, hard efforts like a heavy set. That can let you train a little harder, and training is what builds muscle. Without a training stimulus, creatine has very little to work with. When researchers look at what creatine actually changes in women, the story is led by strength rather than size. A 2021 review by Smith-Ryan, Cabre, Eckerson, and Candow in Nutrients, volume 13, article 877, concluded that creatine supplementation appears effective for improving strength and exercise performance in pre-menopausal women. A 2025 narrative review by Smith-Ryan and colleagues in the Journal of the International Society of Sports Nutrition reported positive effects on muscle strength, exercise performance, and body composition, particularly alongside resistance training. In older adults, the numbers are even more telling. A three-level meta-analysis of creatine combined with resistance training found a significant improvement in muscle strength compared with training alone, with a Hedges' g of 0.31 and a 95 percent confidence interval of 0.18 to 0.45. For muscle mass, the result wasn't statistically significant, with a confidence interval running from negative 0.09 to 0.78. If there's a problem with creatine's effect on size in that research, it's that the effect is modest, not that it's excessive. The 2021 Antonio review also examined a related fear, whether creatine increases fat mass, and concluded it does not. Building noticeably bigger muscles takes years of deliberate, progressive training and eating to support it. Creatine can make that training slightly more productive. It doesn't change the timeline or the effort involved, and it won't do the work for you. Myth 2: "Creatine causes bloating and water weight" This one has a grain of truth in it, which is exactly why it persists. Creatine does draw water into muscle cells. That's part of how it works. The key word is into. This is water stored inside muscle tissue, not the puffy, under-the-skin fluid most people picture when they think of bloating. The 2021 Antonio review addressed water retention directly. Its summary was that while creatine can increase total body water in the short term, particularly during a high-dose loading phase, over longer periods it does not appear to change body water, inside or outside cells, relative to muscle mass. For women specifically, there's a trial designed around exactly this concern. Moore, Gordon, Cabre, Hackney, and Smith-Ryan published a randomized controlled trial in Nutrients in 2023, volume 15, article 429, examining changes in fluid distribution across the phases of the menstrual cycle with creatine supplementation. The finding, as the 2025 review summarized it, was that there was no demonstrated significant increase in body mass for women after creatine monohydrate supplementation in any phase of the menstrual cycle. That's one trial rather than a large body of replicated work, and individual responses vary. But it directly tested the fear in the right population, across the variable women worry about most, and it didn't find the effect. There's also a practical piece. Much of the early water shift, and most of the stomach discomfort people report, comes from loading, which typically means around 20 grams a day split into several doses for about a week. Loading isn't required. Starting at a standard 3 to 5 grams a day reaches the same saturation point, just more slowly, over roughly three to four weeks. If bloating is your main concern, skipping the loading phase is the simplest way to avoid most of what people complain about. Myth 3: "Creatine is basically a steroid" It isn't, and the difference isn't subtle. Creatine is a compound your body makes on its own, from three amino acids: arginine, glycine, and methionine. It's also in food, mainly meat and fish. About 95 percent of the creatine in your body sits in your skeletal muscles, where it's part of normal energy metabolism. Anabolic steroids are synthetic compounds derived from testosterone. They're a completely different class of molecule, with a completely different mechanism, acting on hormone receptors. The Antonio review lists "Is creatine an anabolic steroid?" among the misconceptions it examined, and the answer is no. The related worry, that creatine might disrupt your hormones, has been tested in men more than in women. A 12-week randomized controlled trial published in 2025, discussed in more detail below, found no significant differences between creatine and placebo in total testosterone, free testosterone, or dihydrotestosterone. The women's research runs in a different direction: the 2025 Smith-Ryan review describes how female hormones influence creatine metabolism, not the reverse. What's been measured doesn't support the idea that creatine meaningfully changes hormone levels, though it's fair to say the direct hormonal data in women is limited. Myth 4: "Creatine will make my hair fall out" This fear has a specific origin, and for a long time the evidence on it was surprisingly thin in both directions. It traces back to a small 2009 study in college-aged male rugby players, in which levels of dihydrotestosterone, or DHT, rose over three weeks of creatine supplementation. DHT is the hormone involved in pattern hair loss, so the connection got made quickly and repeated widely. What rarely got mentioned is that the study measured hormones, not hair. That gap was finally tested directly. A randomized controlled trial published in the Journal of the International Society of Sports Nutrition in 2025, titled "Does creatine cause hair loss? A 12-week randomized controlled trial," recruited 45 resistance-trained men aged 18 to 40. They took either 5 grams of creatine monohydrate or 5 grams of a maltodextrin placebo daily for 12 weeks, and 38 completed the study. The researchers measured total testosterone, free testosterone, and DHT, and assessed hair follicle health using a Trichogram and the FotoFinder system, which measure hair density, follicular unit count, and cumulative hair thickness. There were no significant differences between the creatine and placebo groups in DHT levels, the DHT-to-testosterone ratio, or any of the hair measures. The authors described it as the first study to directly assess hair follicle health after creatine supplementation, and as strong evidence against the claim that creatine contributes to hair loss. Two honest caveats. First, the trial was in young men, not women, and no equivalent trial has been done in women yet. Second, several of the authors disclosed industry relationships, including advisory roles with creatine brands. That doesn't make the result wrong, and it lines up with earlier research finding no consistent rise in testosterone with creatine, but it's worth knowing. If you're noticing hair thinning, it has a range of possible causes in women and is worth having a dermatologist look at directly, rather than attributing it to, or ruling it out based on, any single supplement. Myth 5: "Creatine will dehydrate me and give me cramps" This myth was common enough in sports that it drew several dedicated reviews, and they're consistent. A systematic review with meta-analyses by Lopez, Casa, McDermott, Ganio, Armstrong, and Maresh, published in the Journal of Athletic Training in 2009, volume 44, pages 215 to 223, looked specifically at whether creatine hinders heat tolerance or hydration during exercise. None of the included studies showed adverse creatine-induced changes in thermoregulation, percentage of dehydration, urinary hydration measures, or plasma volume. On body temperature, the pooled effect estimate was 0.03, with a 95 percent confidence interval of negative 0.07 to 0.13, meaning no meaningful difference. Controlled trials of athletes exercising in the heat found no adverse effects from creatine at recommended doses. A 2008 review by Dalbo and colleagues in the British Journal of Sports Medicine was titled, fairly bluntly, "Putting to rest the myth of creatine supplementation leading to muscle cramps and dehydration." A 2003 study by Greenwood and colleagues in college football players reported that creatine supplementation during training did not increase the incidence of cramping or injury. The honest limitation is that much of this research was done in athletes, many of them men. The findings are consistent, but they come largely from that population. Myth 6: "Creatine is hard on your kidneys" We've covered this one in detail before, so this is the short version. The International Society of Sports Nutrition's 2017 position stand, by Kreider and colleagues, found no adverse effects on kidney function in healthy adults at recommended doses, and the 2021 Antonio review addressed kidney concerns among its misconceptions. A 2026 structured review in the journal Sports, analyzing randomized controlled trials, was titled "Creatine Supplementation Dose and Duration Are Not Associated with Increased Side Effects." Where the confusion comes from is a blood test. Creatine raises serum creatinine, a waste product that doctors use as a marker of kidney function. In someone taking creatine, a higher creatinine reading reflects the supplement itself rather than kidney damage. If you have bloodwork done, tell your doctor you take creatine so the result gets read correctly. The genuine exception: if you have existing kidney disease, talk to your physician before starting. That's standard guidance for that group, not a general warning. Myth 7: "Creatine is for men" Historically, the research was mostly in men, and that's where this impression comes from. It's changing. "Is creatine only effective for males?" is one of the twelve questions in the 2021 Antonio review, and the review's answer is no. The 2021 Smith-Ryan review and the 2025 review that followed it both report benefits in women for strength, exercise performance, and body composition, especially alongside resistance training. The 2021 review also found that post-menopausal women may see benefits for muscle size and function at higher doses. There are also genuine gaps. The 2025 review notes that data in perimenopausal women remains limited. And the 2021 review states plainly that there are no human studies to date evaluating creatine supplementation during pregnancy. If you're pregnant, trying to become pregnant, or breastfeeding, that's a conversation for your obstetric provider rather than something to decide from a blog post, including this one. What the myths leave out Clearing up the myths doesn't mean there's nothing to think about. The real considerations are just different from the ones people usually worry about. Pregnancy is a genuine gap in the research, as above. Existing kidney disease warrants a conversation with a physician. And expectations matter. The evidence supports creatine as a modest, useful addition to resistance training, particularly for strength. It isn't a shortcut, and people who take it without training usually notice very little. If you do decide to try it, the approach with the most evidence behind it is simple: creatine monohydrate, 3 to 5 grams a day, taken consistently, with no loading phase required. Timing doesn't matter much. Consistency does. We sell creatine monohydrate, and our current batch tested at 4,976 milligrams against a 5,000 milligram label claim. That's the kind of number worth asking any brand for. The honest summary The myths that keep women away from creatine mostly don't survive contact with the research. It doesn't make you bulky on its own: the benefits in women are led by strength, and in older adults the effect on muscle mass wasn't even statistically significant. The bloating fear is mostly about water stored inside muscle, and a 2023 randomized trial found no significant increase in body mass in women across any phase of the menstrual cycle. It isn't a steroid, and the hormonal data available, mostly in men, shows no meaningful effect. The first trial to directly measure hair follicles after creatine, published in 2025, found no effect on hair or DHT, though it was in young men and its authors disclosed industry ties. Reviews spanning more than a decade have found no increase in dehydration or cramping. And the kidney concern is largely a misread blood marker in healthy people. What's genuinely unresolved is narrower: no pregnancy trials, limited perimenopause data, and hair research that hasn't yet been done in women. That's a short list, and it's a much more useful one than the fears it replaces.
Learn more
Strength Training After 40: The Supplement Questions Worth Asking
Strength Training After 40: The Supplement Questions Worth Asking If you started lifting in your 40s, or came back to it after years away, you've probably noticed how fast the supplement conversation shows up. Someone at the gym swears by their pre-workout. An ad promises "anabolic support." A podcast recommends five things you've never heard of. The volume of recommendations tends to run in the opposite direction from the evidence behind them. You don't need to evaluate every product on the shelf. A handful of questions, asked in the right order, sorts out most of them. This post walks through those questions and the research behind each one. Some of the answers point toward a supplement. More of them point somewhere else, and a couple point toward things worth avoiding entirely. First, why strength training is worth doing at all The case for lifting after 40 doesn't depend on anything you can buy. The World Health Organization's 2020 guidelines on physical activity, published by Bull and colleagues in the British Journal of Sports Medicine, volume 54, pages 1451 to 1462, recommend that adults do muscle-strengthening activities at moderate or greater intensity, involving all major muscle groups, on two or more days a week. The WHO rated this a strong recommendation supported by moderate-certainty evidence. For older adults, the guidelines go a step further. As part of their weekly activity, older adults should do varied multicomponent physical activity that emphasizes functional balance and strength training, at moderate or greater intensity, on three or more days a week, to enhance functional capacity and prevent falls. The review behind the guidelines found high-certainty evidence that balance and functional exercises reduce the rate of falls. A 2022 systematic review and meta-analysis by Momma and colleagues, also in the British Journal of Sports Medicine, reported that muscle-strengthening activities are associated with lower risk and mortality across major non-communicable diseases. One more detail from the WHO work is worth knowing. The review found no evidence supporting a dose-response association with higher volumes of muscle-strengthening activity for health outcomes. In other words, the target is two or more sessions a week done properly, not living in the gym. Question 1: Is the training itself actually in place? This comes first because it determines whether any supplement has something to work with. Supplements that help with strength training work on the adaptation to training, not in place of it. We went through the evidence on this in detail in our post on muscle loss in midlife. The short version is that in research on older adults, resistance training consistently does the heavy lifting, and nutrition makes it work somewhat better. Where the two have been compared directly, adding nutritional support to a training program often produced little or no extra benefit over the training program alone. So before anything else, check the basics against the WHO baseline. Are you training all the major muscle groups, legs, hips, back, chest, core, shoulders, and arms, at least twice a week? Is the effort genuinely moderate or harder? The WHO describes moderate intensity, on a scale relative to your own capacity, as usually a 5 or above out of 10. Are you gradually asking your muscles to do a bit more over time, whether that's more weight, more reps, or harder variations? If the answer to any of those is no, fixing it is the highest-return change available to you, and nothing in a tub substitutes for it. Question 2: Is your protein handled before anything else? Protein is the one nutritional input with a direct, well-established role in building and maintaining muscle, so it belongs ahead of any supplement in the queue. We've covered protein after 40 separately, so this is just the part that matters most for training. The total amount matters, but so does how it's spread across the day. The PROT-AGE Study Group, in its 2013 position paper by Bauer and colleagues in the Journal of the American Medical Directors Association, described a higher per-meal threshold for older adults, roughly 25 to 30 grams of protein per meal containing about 2.5 to 2.8 grams of leucine. That recommendation was written for people over 65, but the underlying point, that a meal needs enough high-quality protein to register as an anabolic signal, is a useful habit to build earlier. If you use a protein powder, think of it as a way to make a low-protein meal count, usually breakfast, rather than as a performance product. And source matters here. For the specific job of clearing a per-meal leucine threshold, a whey-dominant protein does it more efficiently than a collagen-dominant one. Our own blend leans toward collagen, and we'd rather tell you that than let you assume it's optimized for this particular purpose. Question 3: What exactly was measured, in whom, and how big was the effect? Once training and protein are in place, this is the question that filters the rest of the shelf. It has three parts. What was measured. Strength, muscle size, physical function, and lab markers are four different things. A supplement can move one without moving the others. Plenty of products cite studies showing a change in a blood marker or a signaling pathway, which is not the same as showing you'll lift more or move better. In whom. A great deal of sports supplement research is done in young, trained men. Results in that group don't automatically carry over to a 45-year-old woman who started lifting last year, or to a 60-year-old man returning after a long break. How big. A statistically significant result can still be small. The confidence interval tells you how precise the estimate is, and whether it plausibly includes no effect at all. Creatine is a useful worked example, because it's the supplement most people in this position ask about, and because the evidence in older adults is genuinely good but narrower than the marketing suggests. A systematic review and three-level meta-analysis of resistance training plus creatine in older adults found a significant improvement in muscle strength compared with training alone, with a Hedges' g of 0.31, a 95 percent confidence interval of 0.18 to 0.45, and moderate certainty of evidence. The same analysis found no statistically significant effect on muscle mass, with a confidence interval of negative 0.09 to 0.78, or on physical function, with a confidence interval of negative 0.08 to 1.03. Run that through the three questions. Measured: strength, yes; mass and function, not significantly. In whom: older adults, which is relevant. How big: small, but with a confidence interval that stays clear of zero. That makes creatine a reasonable addition if strength is your goal and you set realistic expectations. We sell creatine monohydrate, and that's the honest version of the case for it. Question 4: Could it actually work against your training? This is the question almost nobody asks, and it's the one with the most surprising answer. Exercise produces reactive oxygen species, molecules often described simply as oxidative stress. The intuitive move is to neutralize them with antioxidant supplements. But researchers increasingly view some of these molecules as signals that help tell muscle to adapt. Blocking the signal could, in principle, blunt the response. A randomized placebo-controlled trial by Bjørnsen and colleagues, published in the Scandinavian Journal of Medicine and Science in Sports in 2016, volume 26, pages 755 to 763, tested this directly. Thirty-four men aged 60 to 81 followed the same strength training program, three sessions a week for 12 weeks. Half took 500 milligrams of vitamin C and 117.5 milligrams of vitamin E before and after training, and half took a placebo. The placebo group gained more. Rectus femoris thickness, a front thigh muscle, increased by 3.4 millimetres in the placebo group compared with 1.9 millimetres in the supplement group, and leg lean mass rose by around 5 percent versus around 2 percent. The paper's title states the conclusion: vitamin C and E supplementation blunts increases in total lean body mass in elderly men after strength training. Not every measure differed between groups, but the ones that did all pointed the same way. The authors suggested that high-dose antioxidants may suppress the signaling that activates hypertrophy pathways. A follow-up analysis from the same research group, published by Stunes and colleagues in the European Journal of Applied Physiology in 2017, is titled plainly: high doses of vitamin C plus E reduce strength training-induced improvements in areal bone mineral density in elderly men. The evidence isn't one-sided, and it's worth saying so. A 2014 study by Paulsen and colleagues in the Journal of Physiology found that vitamin C and E supplementation altered protein signaling after a strength training session, but not muscle growth over 10 weeks of training. An earlier study by Bobeuf and colleagues in healthy older adults reported a significant gain in lean mass only when resistance training was combined with vitamin C and E. A 2020 review of this literature in the International Journal of Environmental Research and Public Health also cautioned that findings in older adults may not represent athletic populations. So this isn't settled. What can be said is that there's no good evidence that high-dose vitamin C and E supplements help strength training, and there's a well-designed trial suggesting they can blunt gains in older men. These studies tested high-dose supplements, not antioxidant-rich food, which is a separate question. If you're taking high-dose C and E specifically to help your training, the research doesn't support it. Question 5: Is it doing a job your food already does? Branched-chain amino acids, sold as BCAAs, are one of the most common strength training supplements, and they're a clean example of this question. The three branched-chain amino acids are leucine, valine, and isoleucine. A multimillion-dollar supplement category has grown around the idea that taking them on their own stimulates muscle protein synthesis. Robert Wolfe of the University of Arkansas for Medical Sciences examined that claim in a 2017 review in the Journal of the International Society of Sports Nutrition, volume 14, article 30, titled "Branched-chain amino acids and muscle protein synthesis in humans: myth or reality?" His reasoning is straightforward once laid out. Building new muscle protein requires all the essential amino acids, not just three of them. If you take only BCAAs, the other essential amino acids have to come from breaking down existing muscle protein. That puts a hard ceiling on how much new protein BCAAs alone could drive, and Wolfe notes that even his theoretical estimate of that ceiling is an overestimate. His conclusion: the claim that consumption of dietary BCAAs stimulates muscle protein synthesis or produces an anabolic response in human subjects is unwarranted. Complete protein, from food or a quality powder, already contains the branched-chain amino acids along with every other essential amino acid your muscle needs. If your protein intake is in good shape, a standalone BCAA product is paying for a subset of something you're already getting in full. The broader habit is worth keeping. Before buying an isolated ingredient, check whether your diet already supplies it in a more complete form. For a lot of products, it does. Question 6: Is it only what the label says it is? This is the question that matters most for the strength training category specifically, because the documented problems are concentrated here. A 2018 study by Tucker and colleagues at the California Department of Public Health, published in JAMA Network Open, volume 1, issue 6, analyzed the FDA's Tainted Products Marketed as Dietary Supplements database from 2007 through 2016. It found 776 supplements containing unapproved pharmaceutical ingredients, from 146 companies. The three most affected categories were sexual enhancement at 45.5 percent, weight loss at 40.9 percent, and muscle building at 11.9 percent. The muscle building findings are specific. Of 92 adulterated muscle building products, 82, or 89.1 percent, contained synthetic steroids or steroid-like ingredients. Seventy-three contained undeclared anabolic steroids or steroid-like substances. Across all 776 products, 157, or 20.2 percent, contained more than one unapproved ingredient. The authors wrote that adulteration with active pharmaceutical ingredients does not happen by accident. One more detail cuts against a common reassurance. Twenty-eight products were named in more than one warning issued more than six months apart, and of those, 67.9 percent contained new unapproved ingredients in the later warnings. A product being pulled and brought back doesn't mean the problem was fixed. An accompanying editorial by Pieter Cohen in the same issue was titled "The FDA and Adulterated Supplements: Dereliction of Duty," which gives a sense of how the research community read these findings. For practical purposes, the pattern suggests where to be most skeptical: products marketed with aggressive muscle building language, claims of anabolic, steroid-like, or hormonal effects, and proprietary blends that don't disclose amounts. Single-ingredient products with clear documentation are easier to evaluate. For people who need extra assurance, such as competitive athletes subject to drug testing, certification programs such as NSF Certified for Sport exist specifically to screen products for banned substances. It's worth being precise about our own testing here. Our lab reports cover things like potency, microbial safety, and, for some products, heavy metals. They are not banned-substance screens, and we're not going to suggest they are. What that leaves Worked through in order, the questions produce a short and fairly unglamorous list. Training comes first, at the WHO baseline of two or more sessions a week covering all major muscle groups at a genuine effort level, with balance and functional work added as you get older. Protein comes second, with attention to how it's distributed across meals, and a leucine-dense source if clearing that per-meal threshold is your goal. Creatine monohydrate is the one addition with a consistent, if modest, strength benefit alongside training in older adults, supported by moderate-certainty evidence. Standalone BCAAs add little if your protein intake is adequate. High-dose vitamin C and E aren't supported for training and may blunt gains. And products sold with steroid-like or hormonal muscle building claims are the part of the market where adulteration is most documented. We don't sell a standalone BCAA product or a high-dose vitamin C and E supplement, so we have no stake in those two answers either way. The honest summary Strength training after 40 is well supported on its own terms. The WHO recommends muscle-strengthening activity on two or more days a week as a strong recommendation, adds multicomponent balance and strength work for older adults to help prevent falls, and found no evidence that higher training volumes add further health benefit. Supplements sit downstream of that. Asking what was measured, in whom, and how big the effect was turns creatine into a reasonable, modest option for strength rather than a transformation. Asking whether something could interfere turns up a randomized trial in which high-dose vitamin C and E blunted muscle gains in older men, alongside other studies that found smaller or no effects. Asking whether your food already does the job makes standalone BCAAs largely redundant, per Wolfe's 2017 review. And asking whether a product is only what its label says points straight at the muscle building category, where 89.1 percent of the adulterated products in the FDA's database contained steroids or steroid-like ingredients. That's fewer products than most people expect to end up with. It's also a list you can actually defend, which is more than can be said for most of what's on the shelf.
Learn more
Hydration and Hormonal Shifts: What Changes, What Doesn't
Hydration and Hormonal Shifts: What Changes, What Doesn't Few areas of women's health carry as many confident claims with as little measurement behind them as hydration. You retain water before your period. Your hormones mean you need more electrolytes than men. Hot flashes are quietly dehydrating you. Some version of each shows up in marketing aimed at women from their twenties through menopause. The underlying biology is real. Estrogen and progesterone do act on the systems that control thirst and fluid balance, and menopause does change how the body handles heat. But when researchers have actually measured fluid retention, plasma volume, sweat rates, and electrolyte losses, the picture that comes back is much quieter than the claims. Hormones shift some of the body's set points. On average, they change very little about how much water and sodium you end up holding onto. This post walks through both halves: what the research shows changes, and what it shows doesn't. How the body regulates water in the first place A quick grounding, because everything else depends on it. Your body keeps the concentration of your blood, called plasma osmolality, within a narrow range. When it rises, meaning your blood is getting slightly more concentrated, two things happen. You get thirsty, and your brain releases arginine vasopressin, usually shortened to AVP, which signals your kidneys to hold onto water. Sodium balance runs through a related system, with aldosterone signaling the kidneys to retain sodium. As Nina Stachenfeld, one of the leading researchers in this area, has put it, thirst and fluid-regulating hormones respond to both osmotic and volume stimuli. The key word for this post is threshold. Thirst and AVP release don't switch on the moment anything changes. They switch on once plasma osmolality crosses a certain point. And that point, it turns out, isn't fixed. What changes: estrogen moves the set point Much of what's known here comes from Stachenfeld's work at the John B. Pierce Laboratory and Yale University School of Medicine. Her 2008 review in Exercise and Sport Sciences Reviews, volume 36, issue 3, pages 152 to 159, summarizes the core finding: estradiol lowers the operating point for osmoregulation of AVP and thirst, and it increases plasma volume. In plain terms, when estrogen is higher, you start feeling thirsty and conserving water at a slightly lower level of blood concentration than you otherwise would. Your body defends a slightly different target. The research behind this was carefully designed. In a study published in the Journal of Applied Physiology in 1999, Stachenfeld and colleagues took nine women with an average age of 25 through 150 minutes of dehydrating exercise, followed by 180 minutes of drinking freely. Each woman was tested six times in a randomized crossover design: twice in the early follicular phase, twice in the midluteal phase, and after four weeks each of combined estrogen-progestin and progestin-only oral contraceptives. A design like that compares the same women under different hormonal conditions, instead of comparing different women with each other, which removes a lot of noise. Later work went further. To separate estrogen's effects from progesterone's, researchers used a gonadotropin-releasing hormone agonist to temporarily suppress both hormones, then added each back in controlled amounts to mimic different phases of the cycle. That isolates the hormones in a way a natural cycle can't. Progesterone turned out to behave differently from estrogen. A 2001 study by Calzone and colleagues, Stachenfeld among them, in the American Journal of Physiology is titled plainly: progesterone does not alter osmotic regulation of AVP. Progesterone has been observed to affect fluid retention through aldosterone and AVP pathways, and may increase plasma volume independent of estrogen, but a 2021 paper in Frontiers in Sports and Active Living notes that the precise mechanism remains unclear. What this looks like in daily life is subtle. A lower threshold means thirst and water conservation start a little earlier when estrogen is high. That's the body adjusting its target. It is not the body losing control of its fluid balance, and that distinction matters for everything that follows. What doesn't change: how much water you actually hold This is the part that rarely makes it into marketing, and it comes from the same researchers who established the mechanism. In the same 2008 review, Stachenfeld wrote that although reproductive hormones alter the homeostatic set points for body fluid, total body water and sodium content are only mildly affected. The set point moves. The total amount of water and sodium in your body mostly doesn't. A 2022 review from the University of Stirling, by Rodriguez-Giustiniani, Rodriguez-Sanchez, and Galloway in the European Journal of Sport Science, volume 22, issue 5, looked across the research on menstrual cycle hormones and fluid balance and reached a clear conclusion. Despite evidence that estrogen can influence the osmotic threshold for AVP release, and that progesterone can influence aldosterone production, these actions do not appear to influence fluid retention, plasma volume changes at rest and during exercise, or electrolyte losses. The review went further on exercise. Estrogen-dominant phases, such as the late follicular phase, promote heat dissipation. Progesterone-dominant phases, such as the mid-luteal phase, promote heat conservation and a higher basal body temperature. But the authors found these responses do not consistently lead to any change in observed sweat rates, heat stress, or dehydration during exercise. And the literature does not support any difference in fluid retention during post-exercise rehydration across different phases of the cycle. That's a strong set of null findings, and it deserves to be stated as clearly as the mechanism usually is. On average, across the studies reviewed, where you are in your cycle does not meaningfully change how much fluid you retain, how much you sweat, or how many electrolytes you lose. Two honest qualifiers come with it. First, the review authors point out that hormonal fluctuations vary a great deal between individuals, and that women with especially large fluctuations could experience disturbances that averages would hide. They call for more research in exactly that group. Second, premenstrual bloating is a common and genuine experience. The research here is about measured fluid balance, and it doesn't claim to explain every sensation people describe as bloating. What it does say is that a large, measurable swing in body water across the cycle isn't what the average data shows. Where cycle phase can matter: long endurance events There's one specific situation where the research points to paying closer attention, and it runs against the usual advice. Exercise-associated hyponatremia, a dangerous drop in blood sodium during prolonged exercise, is driven largely by drinking more fluid than you're losing, sometimes combined with sodium lost in sweat. We've covered it in detail elsewhere. The relevant point here is a 2009 study by Stachenfeld and Taylor, summarized in the Stirling review, which examined whether sex hormones influence water and sodium regulation in women at high risk of this condition during endurance exercise. More fluid was retained, and more sodium lost, when both estradiol and progesterone were elevated. The authors suggested that when both hormones are elevated, as in the luteal phase, monitoring fluid and electrolyte balance during long-duration endurance events is particularly important, especially for women susceptible to symptomatic hyponatremia. Notice which direction that points. The concern is holding too much water relative to sodium. For most people, that means the priority during a long race or training day in the luteal phase isn't drinking more. It's not overdrinking. What changes after menopause: the thermostat narrows Menopause brings a different kind of shift, centered on heat rather than thirst. Hot flashes are the most common symptom of the menopausal transition. In a 2005 review in the American Journal of Medicine, Robert Freedman of Wayne State University noted that they occur in about 75 percent of perimenopausal and postmenopausal women in Western societies. A 2014 review by Freedman in the Journal of Steroid Biochemistry and Molecular Biology describes a hot flash as a rapid and exaggerated heat dissipation response, made up of profuse sweating, peripheral vasodilation, and feelings of intense internal heat. The mechanism Freedman's research identified is specific. Your body normally holds core temperature inside a neutral zone between two thresholds: an upper one that triggers sweating and a lower one that triggers shivering. Small temperature changes inside that zone get handled quietly, mostly by adjusting blood flow to the skin. In a study published in the American Journal of Obstetrics and Gynecology in 1999, volume 181, pages 66 to 70, Freedman and Krell compared 12 postmenopausal women who had hot flashes with 8 who didn't. In women with symptoms, the zone between the sweating and shivering thresholds, measured by rectal temperature, was essentially gone, at 0.0 degrees Celsius, compared with 0.4 degrees in women without symptoms. Sweat rates were about twice as high in the symptomatic women, 0.06 versus 0.03 milligrams per square centimetre per minute. During exercise, every woman with symptoms had a hot flash and none of the women without symptoms did. The authors concluded that hot flashes may be triggered by small elevations in body temperature acting within a reduced thermoneutral zone. With almost no buffer, a minor temperature rise that another woman's body would absorb without noticing tips straight over the sweating threshold. Estrogen is part of this, but not all of it. Freedman's 2005 review notes that although hot flashes accompany the withdrawal of estrogen at menopause, the decline in estrogen levels is not sufficient to explain their occurrence. Elevated central sympathetic activation, acting through alpha-2 adrenergic receptors in the brain, appears to contribute to narrowing the zone, and more recent reviews also point to increased neurokinin B signaling. It's a brain-level change in temperature control, not simply a hormone deficit. What that means for hydration after menopause This is exactly where marketing tends to run ahead of the evidence, so it's worth being precise. Hot flashes and night sweats involve real sweating, so they involve real fluid loss. That part is simply true. But the studies above characterize how hot flashes work. They don't quantify how much total fluid a typical woman loses to them across a day or night, and none of the research reviewed here shows that hot flashes cause clinically significant dehydration or that electrolyte supplements reduce them. So the defensible version is modest. If you're having heavy night sweats, replacing that fluid makes sense, and for most people water and ordinary meals cover it. Nothing in this research suggests hot flashes create a special electrolyte requirement. The more useful practical point comes straight from the mechanism. If hot flashes are triggered by small rises in core temperature within a narrowed zone, keeping your environment cool is a logical, low-risk step. Freedman's 2014 review notes that peripheral cooling ameliorates hot flashes. A cooler bedroom, lighter bedding, and a fan go after the trigger itself instead of the aftermath. The same review also states that hot flashes account for some, but not all, of the sleep disturbance reported during menopause. If your sleep is badly disrupted, it's worth raising with a clinician, whatever is behind it. So do women need different electrolytes? Pulling it together, the honest answer is: not because of hormones alone. The menstrual cycle shifts thirst and AVP thresholds, but the best available review finds no consistent effect on fluid retention, plasma volume, sweat rates, or electrolyte losses. Menopause changes heat regulation, but the research reviewed here doesn't establish a hormone-driven electrolyte requirement from it. That leaves women with the same reasons to use electrolytes as anyone else: prolonged heavy sweating, hot conditions, long endurance efforts, and certain eating patterns such as very low carbohydrate diets, which increase sodium excretion through a separate mechanism we've covered elsewhere. The one hormone-specific consideration the research does support is the endurance point above, and it's about avoiding overdrinking in the luteal phase, not adding more. We sell an electrolyte product, and we think it's genuinely useful in the situations just listed. We don't think the research supports telling women they need it because of their hormones, so we're not going to. What's worth doing In everyday life, drink to thirst. Hormones shift when thirst kicks in, but they don't break the system, and for healthy adults thirst is a reasonable day-to-day guide. For long endurance events, especially in the luteal phase, watch for overdrinking rather than underdrinking. Weighing yourself before and after a long session is a simple way to check whether your intake roughly matches what you actually lost. If night sweats are frequent, keep your sleeping environment cool and replace fluid normally. There's no need for anything special. And pay attention to changes that don't fit this picture. Persistent, unusual thirst is worth mentioning to a doctor, because it can have causes that have nothing to do with hormones. The honest summary Estrogen genuinely lowers the threshold at which your body triggers thirst and releases vasopressin, and it increases plasma volume. Progesterone doesn't alter osmotic AVP regulation, though it acts through other pathways that aren't yet fully understood. That much of the popular story is real. What doesn't hold up is the idea that these shifts translate into large changes in how much water or sodium you carry. Stachenfeld, whose work established the mechanism, describes total body water and sodium content as only mildly affected. A 2022 review of the menstrual cycle research found no consistent effect on fluid retention, plasma volume, sweat rates, electrolyte losses, or post-exercise rehydration, while noting that women with unusually large hormonal swings may be exceptions. Menopause narrows the body's thermoneutral zone to almost nothing in women with hot flashes, which is why small temperature rises trigger sweating. That's a real change in heat regulation. It isn't evidence of a special hydration or electrolyte need. The practical takeaways are unexciting and well supported: drink to thirst, avoid overdrinking during long efforts in the luteal phase, keep cool if hot flashes are an issue, and don't buy anything on the premise that your hormones require it.
Learn more
Brain Fog in Midlife: Separating Mechanism from Marketing
Brain Fog in Midlife: Separating Mechanism from Marketing Walking into a room and forgetting why. Losing a word you use every day. Rereading the same paragraph three times. Women describe this in almost identical terms during their 40s and early 50s, and for a long time the standard response was some version of "it's stress" or "it's just getting older." That response turned out to be partly wrong. There is now good longitudinal evidence that something measurable happens to cognition during the menopause transition. There is also good evidence about what that something is, how large it is, and how long it lasts. That evidence is considerably more reassuring than the worry it tends to produce, and considerably less useful to supplement marketing than the marketing would like. This post covers what the research actually measured, what it points to as contributing factors, and how the most common "brain fog" products hold up against it. "Brain fog" is a description, not a diagnosis Start with the term itself. Brain fog is not a medical diagnosis. It has no diagnostic criteria, no agreed definition, and no test. Researchers studying it generally use the phrase subjective cognitive complaints, meaning what people report experiencing, and they measure it separately from objective cognitive performance, meaning what people actually score on standardized tests. That distinction matters more than it sounds. A subjective complaint is real. It describes a genuine experience. But it doesn't tell you which mechanism is behind it, and very different causes can produce the same feeling. Poor sleep produces it. Anxiety produces it. Depression produces it. So can thyroid problems, anemia, certain medications, and plain overload. A product sold "for brain fog" is sold for a feeling, which means it can be marketed to almost anyone without claiming to treat anything specific. What the best longitudinal data found The most important research on this comes from the Study of Women's Health Across the Nation, known as SWAN, a multicenter, multiethnic, community-based study that has followed a large cohort of US women through the menopause transition. The key analysis was published by Gail Greendale and colleagues in Neurology in 2009, volume 72, pages 1850 to 1857. They followed 2,362 women over four years and repeatedly tested three cognitive domains: processing speed using the Symbol Digit Modalities Test, verbal memory using the East Boston Memory Test, and working memory using Digit Span Backward. When cognitive testing began, the women's mean age was 50. The design is worth understanding, because the finding depends on it. When people take the same cognitive test several times, they normally get better at it. This practice effect is expected in midlife and shows up reliably in healthy adults. Here is what SWAN found. Women who were premenopausal, early perimenopausal, or postmenopausal improved with repeated administration of the processing speed test, with a p-value at or below 0.0008. Women in late perimenopause did not improve, with a p-value of 0.2. Verbal memory showed a similar perimenopausal decrement. And after the transition, improvement rebounded to premenopausal levels. The authors concluded that perimenopause was associated with a decrement in cognitive performance, characterized by women not learning as well as they had before, and that these difficulties may be time-limited. The detail that changes how this should feel Read that finding carefully, because the popular version of it is not quite what the study showed. A later progress report from the SWAN investigators, led by El Khoudary and published in 2019, spelled out the distinction directly. The perimenopause effect was subtle. It showed up as the absence of a learning effect, not as a drop. As the report puts it, even in perimenopause, test scores did not drop. They simply did not improve during that stage. Not getting better and getting worse are different things. What was measured during the transition was a temporary loss of the usual improvement with practice, and it recovered afterward. The same report noted that approximately 60 percent of midlife women report problems with memory during the transition. So both facts hold at once. The complaint is common and real. The measured change is modest and appears to be temporary. Researchers reviewing this literature have described these changes as occurring without indicating neurodegenerative disease. If you're in your 40s and worried that losing words means something is going badly wrong, this is the most relevant finding available, and it is a reassuring one. Not every study agrees, and that's worth knowing It would be easy to present SWAN as the final word. It isn't, and the literature is honest about that. In a 2010 follow-up paper in the American Journal of Epidemiology, Greendale and colleagues summarized the small body of longitudinal research available at the time. Two of three published longitudinal studies corroborated women's perceptions. The Kinmen Women-Health Investigation found a perimenopause-related deficit in verbal memory. A two-year substudy at SWAN's Chicago site found that processing speed and working memory were unaffected by the transition. The larger four-year analysis across all seven SWAN sites found the transient decrement described above. A 2023 structured review in Frontiers in Aging Neuroscience noted that there has been insufficient research to determine whether these effects are time-limited, and suggested that studies with more repeated assessments across a wider age span would help settle the question. The fairest summary is that the best evidence points toward a modest, domain-specific, probably temporary effect, with some disagreement between studies about exactly which domains are affected. The mechanism question: is it just hormones? The obvious explanation is estrogen. Estrogen acts on the brain, including regions involved in memory, and its levels fluctuate and then decline across the transition. That is a plausible mechanism, and it is where most marketing starts. The evidence complicates it. An earlier cross-sectional SWAN analysis by Luetters and colleagues, published in the Journal of Women's Health in 2007, volume 16, pages 331 to 344, examined whether menopause stage and circulating levels of estradiol and follicle-stimulating hormone were related to cognitive performance. The title states the result: they were not. That was a cross-sectional analysis, so it can't rule out effects that show up over time within individuals. But it does mean the simple story, where a lower estrogen number on a blood test equals worse memory, isn't supported by that data. The transition is clearly involved in some way, since the effect appears during perimenopause and resolves after it. Exactly how is not settled. What SWAN points to as contributors This is the part of the research that usually gets skipped, and it is arguably the most useful. SWAN's own published guidance on memory and cognition notes that sleep and mood problems increase during the menopause transition. It states plainly that lack of sleep is linked to poor memory and difficulty focusing, and that depression and anxiety impair effort and performance on cognitive testing. SWAN women with depressive symptoms performed less well on tests of processing speed. The 2019 progress report found that among women who had no anxiety before the transition, anxiety symptoms became more likely across it, rising from early to late perimenopause and then declining after menopause. It also found that perceived health below very good, and at least one upsetting life event in the past year, carried greater risk of anxiety symptoms than menopause stage did. Life circumstances mattered at least as much as hormonal stage. Put those together and a practical picture emerges. Several things that impair thinking become more common during exactly this window. Sleep gets disrupted, including by night sweats. Anxiety becomes more likely. Mood shifts. Each of these independently makes it harder to concentrate and remember. Whether they fully explain the cognitive effect or sit alongside a direct hormonal one is still being worked out. But they are real, they are measurable, and unlike estrogen levels, many of them can be addressed directly. Separating the transition from aging There is a second thing happening in midlife, and it's easy to confuse with the first. SWAN has also tracked cognitive aging beyond the transition. According to SWAN's published summaries, age-related declines appear in processing speed in the early 50s, in memory around age 58, and in working memory around age 61. The transition-related memory changes appear to be reversible, while persistent declines only become apparent well after menopause. The rate of that longer-term decline isn't the same for everyone. SWAN reports that financial hardship was consistently associated with accelerated cognitive decline. Diabetes, elevated fasting glucose, central obesity, hypertension, and poor heart health were associated with the rate of decline in processing speed. That list is notable for what's on it. The factors associated with how quickly thinking slows with age are largely cardiometabolic and social, not nutritional gaps that a capsule would close. SWAN is careful here too. Its guidance notes that controlling blood pressure, glucose, and weight is important for overall health, and that whether controlling them also lessens cognitive decline is being tested in ongoing clinical trials. That is the right level of confidence, and it's a higher standard than most brain supplements hold themselves to. Where marketing enters The gap between a common, distressing, poorly defined complaint and a modest, temporary, multi-factor explanation is exactly the space supplement marketing fills. So it's worth checking the most common claims against the most rigorous evidence available. Ginkgo biloba. Ginkgo is the most studied memory supplement in the world, and it has been tested in the largest trial of its kind. The Ginkgo Evaluation of Memory study, co-funded by several arms of the US National Institutes of Health, followed 3,069 community-dwelling older adults with normal cognition or mild cognitive impairment. Participants took 120 milligrams of ginkgo extract twice daily or a placebo, across four clinical sites over eight years. The primary results, published by DeKosky and colleagues in JAMA in 2008, volume 300, pages 2253 to 2262, found ginkgo did not reduce the incidence of dementia or Alzheimer's disease. A secondary analysis by Snitz and colleagues in JAMA in 2009, volume 302, pages 2663 to 2670, followed participants for a median of 6.1 years and found ginkgo did not slow the rate of cognitive decline. This trial studied older adults, not women in midlife, which limits how directly it applies. But it is the most rigorous test ever run on the most heavily marketed memory supplement, and it found nothing. If ginkgo had a meaningful effect on memory, a trial of that size and length was well placed to detect it. Creatine. Creatine has become a popular brain fog recommendation, especially for midlife women, and we've covered the evidence in detail elsewhere. The short version: the European Food Safety Authority's expert panel reviewed 21 human intervention studies in 2024 and concluded that a cause-and-effect relationship between creatine supplementation and improved cognitive function had not been established. The mechanism is plausible. The trial evidence isn't there yet. Magnesium. Magnesium, particularly the L-threonate form, is marketed for menopausal cognitive symptoms. The researchers running a clinical trial currently investigating magnesium L-threonate for menopausal symptoms state in their own trial registration that research on its effect on overall menopausal symptoms is rare. Products are being sold on a question the investigators themselves describe as largely open. We sell creatine and a magnesium complex that includes L-threonate. None of the above changes the reasons they can be worth taking, which we've written about separately. But neither is an established treatment for brain fog, and we're not going to describe them that way. Why mechanism isn't enough Every product above has a plausible mechanism. Ginkgo affects blood flow. Creatine supports cellular energy in the brain. Magnesium participates in nerve signaling. Estrogen acts on memory regions. All of this is real biology. In each case, the step from "this is involved in the relevant biology" to "taking this improves the thing people actually care about" either failed when it was tested or hasn't been tested well. That step is the entire difference between mechanism and marketing. A mechanism tells you something might work. Only a controlled trial tells you whether it does. In this area, the trials that exist have mostly been disappointing, and the complaint being targeted is common enough and vague enough that a product can sell well without ever closing that gap. What's worth doing instead Based on what SWAN and related research actually identify, the more defensible priorities are fairly unglamorous. Treat sleep as a cognitive issue, not just a comfort issue. SWAN's guidance links lack of sleep directly to poor memory and trouble focusing. If night sweats or insomnia are breaking up your nights, that's worth raising with a clinician, and it may do more for your thinking than any supplement. Take mood and anxiety seriously. Depressive symptoms were associated with slower processing speed in SWAN, and anxiety becomes more likely across the transition. Both are treatable, and treating them is likely to help cognition along the way. Keep an eye on the cardiometabolic basics that SWAN associates with long-term decline, including blood pressure, glucose, and central weight, while understanding that the trials testing whether controlling them protects cognition are still running. Hormone therapy is a separate medical decision with its own body of evidence. It belongs in a conversation with a clinician, not in a supplement brand's blog, so we're leaving it out here. And watch for the one pattern SWAN specifically flags. Its guidance advises that if memory changes come on suddenly, they should be reported to a primary care provider. Gradual, on-and-off word-finding trouble in your late 40s fits the research pattern described above. A sudden change doesn't, and deserves a proper evaluation. The honest summary Brain fog in midlife is a real and common experience. Around 60 percent of women report memory problems during the menopause transition, according to SWAN. The best longitudinal evidence, SWAN's four-year study of 2,362 women, found a modest effect. During late perimenopause, women didn't show the usual improvement with repeated testing, and that improvement came back after menopause. Scores didn't fall. They stopped rising, temporarily. Not every study agrees on which cognitive domains are affected, and researchers note that more work is needed to confirm the effect is time-limited. The mechanism isn't as simple as circulating estrogen, which SWAN found was not related to cognitive performance in a cross-sectional analysis. The factors SWAN does identify, including disrupted sleep, anxiety, depressive symptoms, and life stress, are common during this window and can be addressed. Against that background, the most marketed products don't hold up well. The largest trial of ginkgo found no effect on dementia or cognitive decline. EFSA found cause and effect not established for creatine and cognition. Researchers studying magnesium L-threonate for menopausal symptoms describe the existing research as rare. That's a less exciting message than most brain fog content offers, and a more useful one. The measured change is smaller than the fear around it. Much of what drives the experience is sleep, mood, and stress. And right now the evidence supports addressing those directly more than it supports buying anything, including from us.
Learn more
Bone Density After Menopause: Where D3, K2, and Protein Fit
Bone Density After Menopause: Where D3, K2, and Protein Fit Three nutrients dominate the conversation about bone health after menopause. All three have more complicated evidence than the marketing suggests, and the complications run in different directions. One has been substantially undercut by large randomized trials and now carries formal recommendations against its routine use for this purpose. One has genuinely mixed trial results. And one spent decades being blamed for harming bone before the research reversed, and now has modestly positive support. This post covers what the evidence actually shows for each, where the honest limits sit, and what the research consistently identifies as mattering more than any of them. What happens to bone after menopause Bone is living tissue in continuous turnover, with osteoclasts breaking down old bone and osteoblasts building new bone. Estrogen plays a regulatory role in keeping that cycle balanced. When estrogen declines through the menopausal transition, resorption begins outpacing formation, and bone density falls. The result is an accelerated loss that is specific to this period rather than a general feature of aging. It is also the reason bone health becomes a more prominent concern for women in midlife than for men of the same age. Osteoporosis itself is a clinical diagnosis with defined criteria and established medical treatments. Nothing in this post addresses treatment, and anyone with diagnosed osteoporosis or osteopenia should be working with a physician rather than substituting nutritional strategies for medical care. What follows is about what nutrition contributes, which is a narrower question. Vitamin D: what the large trials found This is where the evidence has shifted most dramatically, and where the gap between current guidance and popular assumption is widest. The VITAL trial is the central piece of evidence. Published by LeBoff and colleagues in the New England Journal of Medicine in 2022, volume 387, issue 4, pages 299 to 309, it was an ancillary study of a two-by-two factorial randomized controlled trial testing supplemental vitamin D3 at 2,000 IU per day against placebo. The ancillary study included 25,871 participants with a mean age of 67, of whom 51 percent were women, drawn from all 50 US states. Participants were men aged 50 and older and women aged 55 and older, and were not recruited on the basis of vitamin D deficiency, low bone mass, or osteoporosis. The primary endpoints were incident total, nonvertebral, and hip fractures, reported on annual questionnaires and adjudicated by centralized medical record review. The finding: vitamin D3 supplementation did not result in a significantly lower risk of fractures than placebo. One detail is worth emphasizing because it preempts the most common objection. The absence of benefit persisted even among participants with lower baseline 25-hydroxyvitamin D concentrations, below 20 nanograms per millilitre. The null result was not simply an artifact of studying an already-replete population. These findings were corroborated by the DO-HEALTH study in Europe and the D-Health trial in Australia, both of which similarly found no significant reduction in fracture risk among vitamin D-replete older adults. The accompanying editorial by Cummings and Rosen, published in the same issue, was titled "VITAL findings: A decisive verdict on vitamin D supplementation." What the guidelines now say The regulatory and professional response has followed the evidence, and it is more direct than most people realize. The US Preventive Services Task Force, in its 2024 draft recommendation, issued a grade D statement against vitamin D supplementation for the primary prevention of fractures and falls in community-dwelling adults. A grade D recommendation means the task force recommends against the service, having concluded there is no net benefit or that harms outweigh benefits. The stated reasoning cited potential harms including nephrolithiasis, combined with the absence of net benefit observed in trials such as VITAL, in a largely vitamin D-sufficient population. The 2024 Endocrine Society Clinical Practice Guideline similarly advises against empiric vitamin D supplementation in healthy adults younger than 75, and discourages routine screening of serum 25-hydroxyvitamin D levels. Both bodies maintain that supplementation remains appropriate for specific subgroups, including adults aged 75 and older, pregnant individuals, and those at elevated metabolic risk such as people with prediabetes. The scope of these recommendations matters and should not be overstated in either direction. They address primary prevention in community-dwelling adults without known osteoporosis or established deficiency. They do not address people with diagnosed deficiency, diagnosed osteoporosis, or the specific subgroups named above. Vitamin D remains genuinely necessary for calcium absorption, and correcting a genuine deficiency remains a legitimate clinical intervention. What has changed is the case for taking vitamin D as a fracture-prevention measure if you are a generally healthy adult without deficiency. That case has weakened substantially. Vitamin K2: mixed, as covered previously We have written about vitamin K2 and bone in detail elsewhere, including the trials that disagree, so this will be brief. The headline evidence is the Knapen trial, published in Osteoporosis International in 2013, a three-year randomized controlled trial in 244 postmenopausal women aged 55 to 65 taking 180 micrograms of MK-7 daily. It found significantly decreased age-related decline in bone mineral density at the lumbar spine and femoral neck, though not at the total hip, and reduced vertebral height loss. It sits alongside other rigorous trials that found no significant benefit, including a 2010 trial by Emaus and colleagues in 334 Norwegian women using 360 micrograms of MK-7 for one year, a 2020 three-year trial in 142 postmenopausal women with osteopenia using 375 micrograms daily that found no difference from placebo at any measured site, and work by Binkley and colleagues that confirmed vitamin K reduced undercarboxylated osteocalcin as expected while producing no detectable change in bone turnover, density, or geometry. The mechanism, involving K2-dependent carboxylation of osteocalcin, is well established at the biochemical level. Whether that translates into measurable bone outcomes remains genuinely contested, with well-designed trials reaching opposing conclusions. Protein: the reversal worth knowing about Protein has the most interesting history of the three, because the prevailing view was wrong for decades in a specific and identifiable way. The acid-ash hypothesis held that dietary protein, particularly animal protein, generates an acid load that the body neutralizes by drawing calcium from bone, thereby causing bone loss. It was widely accepted, widely taught, and drove recommendations to limit protein intake for bone health. A series of analyses by Fenton and colleagues systematically dismantled it. Their 2009 meta-analysis in the Journal of Bone and Mineral Research, volume 24, pages 1835 to 1840, examined the effect of the acid-ash hypothesis on calcium balance. Their 2011 paper in Nutrition Journal, volume 10, article 41, conducted a causal assessment of dietary acid load and bone disease applying Hill's epidemiological criteria for causality. The hypothesis did not survive that scrutiny, and a subsequent meta-analysis found no evidence for a protective effect of an alkaline diet on bone health. What replaced it is a modestly positive picture, though one with real internal tension worth reporting honestly. An expert consensus paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases and by the International Osteoporosis Foundation, published in Osteoporosis International in 2018, concluded that in older people with osteoporosis, higher protein intake at or above 0.8 grams per kilogram of body weight per day is associated with higher bone mineral density, a slower rate of bone loss, and reduced risk of hip fracture, provided calcium intake is adequate. The Health, Aging, and Body Composition Study found that higher protein intake was associated with lower vertebral fracture risk, with the upper protein tertile, averaging 1.1 grams per kilogram per day, showing 1.8 to 6.0 percent higher mean baseline bone mineral density. The authors concluded that the lower end of the acceptable macronutrient distribution range and the 0.8 gram per kilogram RDA may be suboptimal for bone mineral density preservation in older adults. A meta-analysis of cross-sectional studies attributed a 2 to 4 percent increase in bone mineral density to protein intake above the RDA. Here is the tension. A systematic review and meta-analysis conducted for the National Osteoporosis Foundation and published in the American Journal of Clinical Nutrition pooled six randomized controlled trials and found no difference between higher and lower protein intake on femoral neck bone mineral density, with a pooled mean percentage change of negative 0.14 percent, a 95 percent confidence interval of negative 0.60 to 0.32, and zero statistical heterogeneity. So the observational and cohort evidence associates higher protein intake with better bone outcomes, particularly fracture risk, while the randomized trial evidence on bone mineral density specifically shows no difference. That pattern can reflect several things: that protein affects fracture risk through pathways other than density, such as muscle mass and fall prevention; that observational associations are confounded by overall dietary quality; or that the RCTs were too short to detect changes in a slow-moving outcome. The honest reading: protein is not harmful to bone, which was the older belief and was wrong. The evidence that higher intake actively improves bone density in randomized trials is absent. The evidence associating it with lower fracture risk is real but observational. What the research consistently identifies as mattering more Across this literature, one intervention appears more consistently than any nutrient, and it is not a supplement. Weight-bearing and resistance exercise applies mechanical load to bone, and bone responds to mechanical load by remodelling. This is the same principle underlying why astronauts lose bone density in microgravity and why the loading history of a limb affects its density. It is a direct stimulus rather than a supporting input. There is also a compounding factor specific to fractures rather than density. Most osteoporotic fractures occur as a result of falls. Muscle strength, balance, and reaction time determine fall risk, and all three respond to resistance and balance training. A person with stronger legs and better balance falls less often, and fracture risk is a function of both bone fragility and the frequency of the events that stress it. This is why interventions combining resistance training with nutritional support consistently outperform nutritional support alone in the broader literature on musculoskeletal outcomes in older adults, a pattern we have examined in detail elsewhere. The honest hierarchy Putting this together for bone health after menopause specifically. Weight-bearing and resistance exercise has the most direct mechanism and the strongest case, both for bone loading and for reducing the falls that convert low bone density into actual fractures. Adequate calcium intake remains a foundational requirement, and the ESCEO and IOF protein consensus explicitly conditions its findings on adequate calcium. Adequate protein is supportive and no longer suspect. The old acid-ash concern has been overturned. Higher intake associates with lower fracture risk in cohort data, while randomized trials show no bone density difference. The recommendations at or above 0.8 grams per kilogram per day are reasonable, and overlap with the intake ranges recommended for muscle preservation. Vitamin D remains necessary for calcium absorption, and correcting a genuine deficiency remains legitimate. Taking it as a fracture-prevention measure without deficiency is not supported by VITAL, DO-HEALTH, or D-Health, and both the USPSTF and the Endocrine Society have issued recommendations reflecting that. Vitamin K2 has a well-established biochemical mechanism and genuinely contested trial results, with one three-year trial finding site-specific benefits and several equally rigorous trials finding none. What this means for us We sell a vitamin D3 and K2 product, and the evidence above complicates the case for it more than it supports it. Stating that plainly is the only defensible option. For D3, the honest position is that the fracture-prevention rationale does not hold up for generally healthy adults without deficiency, based on trials involving tens of thousands of participants and reflected in current guidance from two major bodies. Vitamin D still has a real physiological role in calcium absorption, deficiency is still worth correcting, and specific populations still warrant supplementation. But if the reason you are taking D3 is to prevent fractures and you are not deficient, the large randomized trials do not support that expectation. For K2, the position we have held across previous posts stands: promising mechanism, genuinely mixed trial results, not established. Anyone wanting to know their actual vitamin D status can have it measured, though it is worth noting that the Endocrine Society's 2024 guidance specifically discourages routine screening in healthy adults under 75, which is itself a signal about how the field now views population-wide vitamin D management. The honest summary Bone loss accelerates after menopause because estrogen's regulatory role in bone turnover diminishes. That is real and worth taking seriously. Vitamin D3 supplementation did not reduce fracture risk in VITAL, a trial of 25,871 participants, and the null result held even in those with lower baseline vitamin D levels. DO-HEALTH and D-Health corroborated it. The USPSTF issued a grade D recommendation against supplementation for primary fracture prevention in community-dwelling adults in 2024, and the Endocrine Society advises against empiric supplementation in healthy adults under 75. Vitamin K2 has a solid biochemical mechanism and contradictory trial results, with rigorous studies on both sides. Protein is the most improved story: the decades-long belief that it harms bone was overturned by Fenton and colleagues, and current expert consensus associates intake at or above 0.8 grams per kilogram with better bone outcomes, though randomized trials show no bone density difference and the positive findings are observational. And exercise, specifically weight-bearing and resistance training, remains the intervention with the most direct mechanism and the clearest role, both in loading bone and in reducing the falls that turn low density into fractures. That is a less supplement-friendly conclusion than most content on this topic reaches. It is what the trials found.
Learn more
Magnesium and Hormonal Change: What the Evidence Actually Supports
Magnesium and Hormonal Change: What the Evidence Actually Supports Magnesium is marketed for essentially every hormone-related complaint a woman might have: premenstrual symptoms, perimenopausal mood changes, hot flashes, cortisol regulation, thyroid function. The mechanistic reasoning offered is usually plausible, and the confidence of the claims is usually high. The clinical evidence does not match that confidence. In several of these areas it points the other way, and in at least one case the most frequently cited supporting study has a methodological problem that explains a great deal about why the result looked as good as it did. This post separates the mechanism from the outcomes, examines what the trials actually found, and identifies the one area where magnesium's evidence in this context is genuinely reasonable. It is a narrower conclusion than most content on this topic offers. The mechanism is real, and mechanism is not evidence Magnesium participates in a large number of physiological processes relevant to hormonal function. It influences GABA signalling, the brain's primary inhibitory neurotransmitter system. It plays a role in the regulation of the stress response, including pathways involving cortisol. It is involved in processes touching serotonin, norepinephrine, and thyroid-stimulating hormone. It is required for the enzymatic activity underlying a broad range of metabolic functions. All of that is accurate and none of it is in dispute. What it establishes is that magnesium could plausibly influence hormone-related symptoms. It does not establish that supplementing magnesium does influence them in a measurable, clinically meaningful way. That second question requires clinical trials, and this is precisely where the gap between marketing and evidence opens up. The distinction matters because mechanistic plausibility is abundant in nutrition science and frequently fails to translate. A compound can participate in a relevant pathway and still produce no detectable change in the outcome people actually care about, either because the pathway was not the limiting factor, or because supplementation does not shift it far enough to matter. Premenstrual symptoms: what the reviews concluded Premenstrual syndrome affects roughly 48 percent of women of reproductive age worldwide, and magnesium is one of the most commonly recommended nutritional interventions for it. The evidence base is worth examining directly. A systematic review of randomized controlled trials examining nutritional interventions for the psychological symptoms of premenstrual syndrome, published in Nutrition Reviews in 2025, volume 83, issue 2, reached a specific conclusion about magnesium. The review found insufficient evidence to support the effects of vitamin B1, vitamin D, whole-grain carbohydrates, soy isoflavones, dietary fatty acids, magnesium, multivitamin supplementation, or PMS-specific diets on psychological premenstrual symptoms. Magnesium appears in that list by name. This is a systematic review of randomized controlled trials concluding that the evidence for magnesium in this application is insufficient. There is one finding worth reporting alongside it, because it is more nuanced than a flat negative. The same review describes a randomized crossover study of 44 British women with PMS in which a daily combination of 200 milligrams of magnesium and 50 milligrams of vitamin B6, taken for one month, produced a significant decrease in anxiety-related symptoms including nervous tension, mood swings, irritability, and anxiety, compared with single nutrients or placebo, with a p-value of 0.04. Read that carefully. The combination outperformed single nutrients. Which means magnesium on its own, tested within the same study, did not produce the effect. The review's overall assessment of combined nutrient and multivitamin supplements for psychological PMS symptoms was that the evidence remains limited. A separate systematic review and meta-analysis of observational studies examining the association between serum magnesium levels and premenstrual syndrome, covering 13 studies, described the findings across the literature as inconclusive. For context on what better evidence in this area looks like: a systematic review and meta-analysis of randomized controlled trials examining exercise for premenstrual syndrome found reduced global PMS symptom scores with a standardized mean difference of negative 1.08 and a 95 percent confidence interval of negative 1.88 to negative 0.29. Even that result came with substantial heterogeneity at 87 percent and with 87 percent of included trials assessed at high risk of bias, leading the authors to conclude that exercise may be effective but some uncertainty remains. That is what a cautiously positive finding looks like in this field. The magnesium literature does not currently reach it. Menopause and hot flashes: the study that gets cited, and the problem with it This section requires more care than the last, because the commonly cited evidence looks stronger than it is for a specific and identifiable reason. The most frequently referenced study is a pilot phase II trial conducted at the Mayo Clinic and published by Park and colleagues in 2011, examining magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Participants took 400 milligrams of magnesium oxide at bedtime, increasing to 400 milligrams twice daily after two weeks if symptoms had not improved. The reported results were substantial: greater than 50 percent decreases in fatigue, distress due to hot flashes, and severity of abnormal sweating. Those are impressive numbers, and they are widely quoted. The trial was a phase II pilot. A subsequent larger randomized controlled trial, conducted as NCCTG N10C2 through the Alliance cooperative group and described as a double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes, found smaller effects than the pilot had suggested. The reason that pattern matters is specific to this symptom. Hot flashes are unusually responsive to placebo, and the evidence for this is direct rather than theoretical. A randomized sham-controlled trial testing acupuncture for menopausal hot flashes found that both the real acupuncture group and the sham group improved equally. The intervention and the convincing imitation of the intervention produced the same result. When a symptom responds that strongly to placebo, an uncontrolled or open-label pilot study will systematically overstate an intervention's effect, and the effect will shrink when a proper placebo control is introduced. That is precisely the pattern observed between the 2011 pilot and the larger controlled follow-up. This is not a criticism of the original researchers, who conducted a pilot study and labelled it as such. It is a criticism of how that pilot gets cited, frequently without the phase II designation and without the subsequent controlled trial that qualified it. It is also worth noting that the British Menopause Society does not currently list magnesium as a first-line treatment for menopausal symptoms. Magnesium L-threonate and menopause: the evidence gap stated by researchers Magnesium L-threonate is increasingly marketed for menopausal symptoms on the strength of its ability to cross the blood-brain barrier more effectively than other forms. The mechanistic argument is reasonable. The evidence specific to menopause is essentially absent, and this can be verified from an unusually direct source: the registration documents for a clinical trial currently investigating exactly this question. That trial registration states that randomized controlled trials involving magnesium L-threonate have only confirmed improvement effects on pain and cognitive function, and that research on its effect on improving overall menopausal symptoms is rare. That is researchers setting up a study to answer a question, stating plainly in their own trial documentation that the question has not yet been answered. Any product currently marketing magnesium L-threonate for menopausal symptoms is making a claim ahead of the evidence its own investigators acknowledge is missing. Cortisol and the stress response Magnesium's involvement in stress response regulation is frequently cited as a reason it should help with perimenopausal anxiety and stress reactivity. A systematic review examining the efficacy of magnesium supplementation for subjective measures of anxiety and stress noted that magnesium status is associated with subjective anxiety, which has led to the proposition that supplementation may attenuate anxiety symptoms. The review's assessment of the underlying literature was that the quality of some of the reviewed studies was questionable, and that well-designed randomized controlled trials are needed. Note the structure of that association claim as well. Magnesium status being associated with anxiety is an observational finding, and it runs in both directions: low magnesium could contribute to anxiety, or chronic stress could deplete magnesium, or an unmeasured third factor could drive both. Observational association does not establish that supplementing will reverse the relationship. Where the evidence is genuinely better There is one area where magnesium's evidence in this population holds up reasonably well, and it is worth identifying precisely because the rest of this post has been negative. Sleep. Around 60 percent of women in perimenopause and menopause report sleep disturbance according to NICE guidance, making it the most common complaint in this population. A randomized controlled trial published in the Journal of Research in Medical Sciences found that older adults taking 500 milligrams of magnesium daily for eight weeks fell asleep faster, slept longer, and showed higher melatonin levels compared to placebo. We have covered magnesium and sleep in detail elsewhere, including its limitations, and will not repeat that here. What is worth adding in this specific context is a distinction that usually gets collapsed. The sleep evidence is not hormone-specific. The trial above was conducted in older adults, not specifically in menopausal women, and the mechanism proposed, involving GABA activation and general nervous system calming, is not a hormonal mechanism. If magnesium improves sleep in perimenopausal women, the most likely explanation is that it improves sleep in people generally, and perimenopausal women are people who frequently have disrupted sleep. That is still useful. Sleep disruption is the dominant complaint in this population, and improving it would matter regardless of the mechanism. But it is a different claim than magnesium addressing hormonal change, and conflating the two makes the evidence look broader than it is. It is also worth noting the plausible indirect pathway: if magnesium improves sleep, and poor sleep worsens mood, stress reactivity, and the subjective burden of other symptoms, then downstream improvements could follow without magnesium acting on hormonal pathways at all. Several sources describing women's experience note that those who report hot flash improvement typically notice it alongside better sleep and reduced anxiety, which is consistent with a general nervous system effect rather than a direct hormonal one. What this adds up to The honest hierarchy for magnesium in the context of hormonal change looks like this. For sleep, the evidence is reasonable, the mechanism is plausible, and the relevance to this population is high given how common sleep disruption is. This is the strongest case and it is not a hormonal claim. For premenstrual psychological symptoms, a 2025 systematic review of randomized controlled trials found insufficient evidence for magnesium specifically, with one crossover study suggesting a magnesium and B6 combination may outperform either nutrient alone in a small sample. For hot flashes, the widely cited positive finding came from a phase II pilot, a larger placebo-controlled trial found smaller effects, and the symptom in question is documented to respond strongly to placebo, which explains the discrepancy. For cortisol and stress reactivity, the mechanistic involvement is real, the observational associations exist, and the intervention literature has been assessed as questionable in quality by the researchers reviewing it. For magnesium L-threonate and menopausal symptoms specifically, the investigators currently studying the question state in their own trial documentation that the research is rare. None of this means magnesium is not worth taking. Adequate magnesium intake matters for reasons well established independently of hormonal considerations, and a meaningful share of adults fall short of recommended intake from diet alone. Correcting a genuine shortfall is a reasonable thing to do. What it means is that the specific claim that magnesium addresses hormonal change is considerably less supported than the volume of marketing around it would suggest, and that the most defensible reason to take it in this context is the least glamorous one: sleep support, which is not a hormonal mechanism, in a population that happens to have a high prevalence of sleep disruption. The honest summary Magnesium participates in pathways relevant to hormonal function. That is mechanism, and mechanism is a hypothesis rather than a finding. The clinical evidence, examined directly: insufficient for premenstrual psychological symptoms according to a 2025 systematic review naming magnesium specifically. Promising in a phase II pilot for hot flashes, smaller in the larger controlled follow-up, in a symptom documented to respond strongly to placebo. Questionable in quality for anxiety and stress according to the review assessing it. Explicitly rare for magnesium L-threonate and menopausal symptoms according to researchers currently studying it. Reasonable for sleep, which is not a hormonal mechanism but is the most common complaint in this population. That is a narrower and less satisfying answer than the confident version circulating in this category. It is the one the published trials support, and it is the one worth making decisions on.
Learn more
Muscle Loss in Midlife: The Nutrition Side of the Conversation
Muscle Loss in Midlife: The Nutrition Side of the Conversation There is a framing problem with most content on this subject, and it is worth naming before anything else. Muscle loss in midlife gets discussed as a nutrition problem with a nutrition solution. Eat more protein, add the right supplements, and the decline slows. The research tells a different story, one where nutrition genuinely matters but occupies a supporting role rather than the leading one, and where the evidence for nutrition acting alone is considerably weaker than the marketing around it suggests. This post covers what the clinical research actually establishes: how muscle loss is defined and measured, what the real rates are, what nutrition contributes, and where the evidence stops. The honest version is more useful than the flattering one, particularly for anyone making decisions based on it. What is actually being measured The clinical term is sarcopenia, and its definition changed in a way that reveals something important about the condition itself. The European Working Group on Sarcopenia in Older People published its original diagnostic criteria in 2010, built primarily around low muscle mass. In 2019, the revised consensus, published as Cruz-Jentoft and colleagues in Age and Ageing, volume 48, issue 1, pages 16 to 31, made a significant change: it elevated low muscle strength to the primary diagnostic criterion, with muscle quantity serving as confirmation rather than the starting point. That shift was not arbitrary. It reflected accumulating evidence that strength predicts adverse outcomes better than mass does, and that the two do not decline at the same rate. Under EWGSOP2, the diagnostic pathway runs in stages. The SARC-F questionnaire, with a score of 4 or above, is used to identify people who may have sarcopenia. Grip strength and chair stand tests confirm low muscle strength. DXA and BIA are recommended for evaluating muscle quantity in usual clinical care, with DXA, MRI, or CT in research settings. Measures of physical performance, including the Short Physical Performance Battery, Timed Up and Go, and the 400-metre walk test, are used to assess severity. Severe sarcopenia is defined as poor physical performance alongside both low strength and low muscle quantity. Prevalence in community healthcare settings has been reported to reach up to 29 percent among older adults. The rates, and the detail most summaries miss EWGSOP2 describes muscle mass and strength as generally increasing through youth and young adulthood, reaching maximal levels up to roughly age 40, being maintained through midlife, and then declining with ageing. The specific figures cited in that consensus are worth reading carefully. Beyond age 50, reported losses run at 1 to 2 percent per year for leg muscle mass, and 1.5 to 5 percent per year for strength. Strength declines faster than mass. In some estimates, considerably faster. That asymmetry is the single most useful fact in this entire literature, and it gets almost no attention in consumer content. It means the thing you lose first, and fastest, is not size. It is the ability to produce force, which is what actually determines whether you can carry groceries up stairs, catch yourself when you stumble, or get out of a chair without using your arms. It also explains why EWGSOP2 reorganized its criteria around strength. If you monitor only muscle mass, you are tracking the slower-moving variable and missing the one more closely tied to function. Separately, multiple prospective studies have reported skeletal muscle mass decreasing by roughly 6 percent per decade after middle age, which is broadly consistent with the annual figures above. Where nutrition enters, and what it can actually do Here is where the evidence gets genuinely messy, and where honest reporting requires acknowledging contradictory findings rather than selecting the convenient ones. Protein without exercise. The results are inconsistent. Some clinical trials have found that diets providing 1.5 to 1.6 grams of protein per kilogram per day improved muscle mass without exercise, compared to diets providing 0.8 to 1.2 grams per kilogram, in older adults whose habitual intake sat around 0.8 to 1.1 grams per kilogram. Other work points the opposite direction. Tieland and colleagues found that protein supplementation of 0.41 grams per kilogram per day did not improve muscle mass without exercise when compared against an isocaloric placebo. A 2024 systematic review and meta-analysis examining dose, frequency, and timing of protein supplementation reported improved muscle mass gain from protein supplementation without exercise interventions, explicitly noting that this contradicted the findings of a recent earlier meta-analysis. So: the literature contains studies pointing both ways, and meta-analyses that disagree with each other. Anyone presenting protein-without-exercise as an established intervention for midlife muscle loss is describing a more settled field than exists. Protein with resistance training. This combination has stronger support, but the findings are more qualified than usually reported. A network meta-analysis of 38 randomized controlled trials involving 2,610 participants found that combining protein supplementation with resistance training significantly improved lean body mass compared to protein supplementation alone, with a standardized mean difference of 0.44 and a 95 percent confidence interval of 0.05 to 0.95. But the same analysis found no differences on any outcome when comparing the combined treatment against resistance training alone. Adding protein to a resistance training program did not outperform the training program by itself. The authors described the effects of combining protein supplementation and resistance training in healthy older adults as remaining largely controversial. A separate systematic review and meta-analysis specifically examining whey protein supplementation during resistance exercise training in older people with sarcopenia did find whey more effective than training alone for handgrip strength and skeletal muscle mass. The authors then qualified that finding directly: the effect sizes were small, the mean difference did not exceed the minimally important clinical difference, and the quality of evidence was rated low to very low under the GRADE framework. That is a research team reporting a positive result and then telling readers not to over-interpret it. Worth respecting rather than skipping past. The strongest combined finding. A network meta-analysis covering 96 studies and 7,596 participants found that resistance and balance training combined with protein-based nutritional supplementation was the most effective intervention across multiple outcomes: grip strength improved by a mean difference of 5.45 kilograms, gait speed by 0.20 metres per second, Short Physical Performance Battery score by 3.59 points, and skeletal muscle index by 0.95 kilograms per square metre. Note the structure of that finding. The winning intervention is training plus nutrition. Nutrition appears as a component of the most effective approach, not as the approach itself. Creatine, reported honestly Creatine has the most specific recent evidence in this population, and the numbers deserve to be reported with their confidence intervals rather than summarized as a positive result. A systematic review and three-level meta-analysis examining resistance training combined with creatine supplementation in older adults found that creatine plus resistance training significantly improved muscle strength compared to resistance training alone, with a Hedges' g of 0.31 and a 95 percent confidence interval of 0.18 to 0.45. The certainty of evidence for that outcome was rated moderate. The other two outcomes did not reach statistical significance. Muscle mass showed a pooled effect of 0.35 with a confidence interval of negative 0.09 to 0.78, rated low certainty. Physical function showed 0.47 with a confidence interval of negative 0.08 to 1.03 and a p-value of 0.086, rated very low certainty. So the honest summary for creatine in older adults: a small but statistically robust benefit for strength when added to resistance training, with moderate-quality evidence. No statistically significant effect on muscle mass or physical function in this analysis. Moderator analyses did not identify creatine dose, loading phase, intervention duration, training frequency, training intensity, sex, or testing site as stable sources of variation in the effect. A small strength benefit with moderate certainty is a genuinely reasonable thing to pursue. It is not the same claim as creatine preventing age-related muscle loss, and the difference matters. The hierarchy the evidence actually supports Putting this together produces a clear ordering, and it is not the ordering supplement marketing implies. Resistance training is the primary intervention. It appears in every effective protocol in this literature. Where nutrition has been tested against it head to head, training alone frequently matches combined approaches. Where combined approaches win, training is the component doing the heavy lifting. Adequate protein is the necessary foundation, not the active lever. Protein supports the adaptive response to training. In the absence of training, its independent effect on muscle mass is inconsistent across the literature and disputed between meta-analyses. Creatine is a modest, evidence-supported addition to a training program, with a small but reasonably certain benefit for strength specifically. Other nutritional interventions, including omega-3 fatty acids and vitamin D, have been examined in this population with mixed and generally smaller effects. A systematic review and meta-analysis of omega-3 supplementation with or without resistance training in older adults, covering 16 studies and 2,438 participants, found effects that were inconsistent across measures. What this hierarchy means practically: if you are not doing resistance training, changing your protein intake is unlikely to be the deciding factor in your muscle trajectory. If you are doing resistance training, adequate protein makes that training more productive, and creatine adds a small increment on top of that. Why midlife specifically EWGSOP2 places peak muscle mass and strength at around age 40, with maintenance through midlife and decline thereafter. The measurable acceleration in the figures cited above begins beyond age 50. Midlife is therefore not when the decline is steepest. It is when the trajectory is being set. The muscle mass and strength you carry into your 50s and 60s determines how much you can afford to lose, and resistance training adaptations come more readily before anabolic resistance becomes pronounced than after. That is the honest case for paying attention at 40 to 50: not that requirements have changed dramatically, but that the intervention with the strongest evidence, resistance training, is easier to start and more productive now than it will be later. What is worth doing with this The practical implications follow directly from the hierarchy. Resistance training deserves the largest share of attention and effort, because that is where the evidence concentrates. Two to three sessions per week involving progressive loading is the intervention that appears in essentially every effective protocol in this literature. Adequate protein supports that training rather than substituting for it. The PROT-AGE and ESPEN recommendations of 1.0 to 1.2 and 1.0 to 1.5 grams per kilogram per day respectively are directed at adults over 65, and distribution across meals may matter as much as the daily total, given that muscle protein synthesis reaches a plateau at roughly 0.40 grams per kilogram per meal in older adults compared to 0.24 in younger adults. Creatine at standard doses is a reasonable addition alongside training, with realistic expectations set by the effect sizes above. And if you want to track whether any of this is working, strength measures are more informative than scale weight or body composition estimates, for the same reason EWGSOP2 made strength its primary criterion. Grip strength and chair stand performance are both measurable at home, change faster than mass, and correspond more closely to the function that actually matters. The honest summary Muscle loss in midlife is real, measurable, and clinically defined. Strength declines faster than mass, at roughly 1.5 to 5 percent per year beyond age 50 compared to 1 to 2 percent for leg muscle mass, which is why the current diagnostic consensus was reorganized around strength rather than size. Nutrition is one side of this conversation, and it is the smaller side. The evidence for protein supplementation without exercise is genuinely contradictory, with meta-analyses reaching opposing conclusions. The evidence for protein alongside resistance training is better but qualified, with one large network meta-analysis finding no advantage over resistance training alone and a sarcopenia-specific review reporting small effects that did not exceed the minimally important clinical difference, at low to very low evidence quality. Creatine plus resistance training produces a small, moderate-certainty benefit for strength, with no statistically significant effect on mass or physical function in the most recent three-level meta-analysis. Resistance training is the intervention with the strongest evidence. Nutrition makes it work better. Presenting it the other way around would be easier to sell and harder to defend, and the research does not support it.
Learn more